前往化源商城

116-32-5 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3868897
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2016
Volume: 79
Issue: 9
First Page: 2324
Last Page: 2331
DOI: 10.1021/acs.jnatprod.6b00469
Standard TypeStandard RelationStandard ValueStandard Units
Activity=82.7%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor10.153140.755621Partial curve; partial efficacy-4.99340.40.7519-22.755618-2.20 0 0 0 0 0 0 0 0 0 0 0-18.96314.228615.423221.78321.990312.7098.251211.76180.02953.02123.5483.2806-18.963QC'd by NCI-NPB
Inhibitor70.794641.186310Single point of activity-4.153.06540.7616-40.68630.5-30 0 0 0 0 0 0 0 0 0 0 0-30.5719-5.82211.70573.85692.3906-3.0434-5.1259-0.0204-4.50967.67922.2068-0.8314-30.5719QC'd by SigmaAldrich
Inhibitor20.258137.67710Partial curve; partial efficacy; poor fit-4.69340.60.8367-32.1775.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.48087.31197.43618.07377.8115-1.654-1.67136.0557-3.6601-2.9743-2.3177-14.0308-23.4808QC'd by NCI-NPB
Inhibitor16.091637.601210Partial curve; partial efficacy; poor fit-4.79341.13410.8452-30.60127-2.40 0 0 0 0 0 0 0 0 0 0 0-24.2519.691212.09586.967813.07042.3816-4.34997.21867.4852.3057-3.9474-15.5947-24.251QC'd by NCI-NPB
Inactive0-5.54.95490.59534.5-6.942940 0 0 0 0 0 0 0 0 0 0 05.5505-12.581-3.6735-0.3298-5.7361-15.7857-1.8915-7.6677-3.58716.49081.87073.07685.5505QC'd by NIEHS
Inactive0-5.34.95490.51875.50.001740 0 0 0 0 0 0 0 0 0 0 03.4570.4546-1.44463.17460.2283-1.07621.529-0.8791-2.08193.819910.29192.23513.457QC'd by Labotest
Inactive000414.77677.975815.1119.93217.842411.36965.53624.83674.11242.91079.735117.294514.7767QC'd by Microsource
Inactive00047.48485.14659.28654.05173.33396.02881.82297.78417.71411.52646.27186.01687.4848QC'd by SigmaAldrich
Inactive0-4.44.95490.4225-2.299911.540 0 0 0 0 0 0 0 0 0 0 0-0.249911.032112.73438.29587.7656.439510.40716.53437.858915.144413.27616.7991-0.2499QC'd by FLUKA
Inactive00044.71299.82915.22989.11547.79320.69023.11126.00811.17723.21623.76586.64644.7129QC'd by Timtec
Inactive0-5.21.34430.52729-4.545640 0 0 0 0 0 0 0 0 0 0 08.55970.32651.3817-2.9939-6.7498-13.3714-9.4912-0.51632.79663.1192-0.47189.56148.5597QC'd by ASDI
Inactive0004-3.5795-4.3598-0.5776-3.2591-6.8076-5.0883-8.613-3.3668-6.4244-6.5159-4.2276-4.6923-3.5795QC'd by SigmaAldrich
Inactive0004-13.4251-8.7965-1.2528-9.2469-7.9021-3.3764-1.4523-13.4156-8.74672.7588-1.4294-13.8991-13.4251QC'd by Enamine
Inactive0004-9.8167-11.8528-7.2424-12.0513-7.4969-8.9732-12.2154-12.0728-9.5269-6.1546-3.8393-4.0575-9.8167QC'd by Enamine
Inactive0-51.92820.56798-1.469940 0 0 0 0 0 0 0 0 0 0 06.0779-0.0024-0.20133.1935-0.4054-9.5582-2.4938-2.18322.51884.45953.186311.92486.0779QC'd by Enamine
Inactive0-5.354.95490.76345.5-5.365240 0 0 0 0 0 0 0 0 0 0 06.0484-8.1291-5.3769-2.77281.7572-8.221-7.0739-5.55873.9782.57455.20226.39186.0484QC'd by SIGMA
Inactive0-4.451.10.5944321.51440 0 0 0 0 0 0 0 0 0 0 19.85350.7672-4.57174.81875.40172.6732-2.94765.81258.301312.52973.147124.82849.8535QC'd by SIGMA
Inactive0-5.350.60.65698.5-6.764740 0 0 0 0 0 0 0 0 0 0 04.5331-5.4295-8.5539-2.72830.1802-7.8806-0.2857-2.14165.38450.02812.39559.85114.5331QC'd by LightBiologicals
Inactive0004-5.3594-8.871-12.8425-6.6113-4.5224-10.2103-10.3208-6.0527-14.4677-12.9358-16.9058-11.3122-5.3594QC'd by SIGMA
Inactive0-4.351.13410.555112-1.306940 0 0 0 0 0 0 0 0 0 0 08.9371-6.0891-1.9072-0.54095.0417-4.9288-1.0154-0.45852.45211.48640.16.07468.9371QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor0.064134.705122Complete curve; partial efficacy-7.19340.80.8198-15.205119.5-1.20 0 0 0 0 0 0 0 0 0 0 0-18.427412.341830.693411.06878.702711.1596-4.0097-0.7424-17.7591-18.9041-6.35-11.9997-18.4274QC'd by NCI-NPB
Inhibitor0.057143.182922Complete curve; partial efficacy-7.24340.30.8029-17.182926-1.20 0 0 0 0 0 0 0 0 0 0 11.79619.343712.079420.15979.87981.19632.351-1.4583-2.3569-9.52431.5791-17.65241.796QC'd by NCI-NPB
Inhibitor1044.889521Partial curve; partial efficacy-50.50.7545-32.389512.5-2.20 0 0 0 0 0 0 0 0 0 0 0-24.45936.37118.740215.923510.6417-2.33847.0423-0.518-9.6117-3.1015-13.119-5.0111-24.4593QC'd by Specs
Inhibitor25.1189202.453110Single point of activity-4.64.95490.8549-206.4531-4-30 0 0 0 0 0 0 0 0 1 0 0-157.118-4.9883-9.5737-8.2214-6.9034-18.4403-0.8015-24.8599-8.40283.7254107.134129.6841-157.118QC'd by Analyticon
Inhibitor5.011944.96610Partial curve; partial efficacy; poor fit-5.30.40.7248-41.4663.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.2895.976-6.5685-4.0459-5.1171-3.6133-8.2625-11.6513-11.3707-17.7211-9.4112-34.555-23.289QC'd by Analyticon
Inhibitor10Single point of activity00-3-31.2598-4.64091.1143-7.1165-26.93820.15-13.91455.77672.71096.231732.3237-10.1053-31.2598QC'd by SIGMA
Inhibitor57.095176.982710Single point of activity-4.24344.95490.8136-167.97549.0073-30 0 0 1 0 0 0 1 0 0 0 0-125.3564-2.5428-0.74036.0074-119.4048-11.1656-3.8852-1.9563-143.01776.318137.620550.1208-125.3564QC'd by NCI-NPB
Inhibitor28.615381.180810Partial curve; partial efficacy; poor fit-4.54342.72020.7315-71.96919.2117-2.40 0 0 0 0 0 0 0 1 0 0 0-65.0709-9.34540.0654-8.67176.944226.239712.80327.63739.597675.75736.8623-21.7124-65.0709QC'd by NCI-NPB
Inhibitor28.6153146.918310Single point of activity-4.54344.95490.9263-140.53826.3801-30 0 0 0 0 0 0 0 0 1 1 0-138.6637-0.54878.3171-2.0665.2057-1.8734-6.119911.73982.179639.669148.4234165.9679-138.6637QC'd by NCI-NPB
Inhibitor10Single point of activity00-3-30.74153.15832.3786-4.6143-4.83942.05472.0009-1.0351-6.02710.6182-19.358410.4489-30.7415QC'd by Analyticon
Inhibitor6.309658.840410Partial curve; partial efficacy; poor fit-5.20.60.417-65.9909-7.1505-2.40 0 0 0 0 0 0 0 0 0 0 1-28.9537-10.278-7.0923-12.3469-20.4971-17.6764-24.1328-4.8477-2.6254-57.8867-28.7749-43.6104-28.9537QC'd by Adooq
Inhibitor7.943335.709610Partial curve; partial efficacy; poor fit-5.11.62660.6292-32.20963.5-2.40 0 0 0 0 0 0 1 0 0 0 0-31.2215-8.6776-0.010226.2164.2017-7.6517-3.874711.94249.9824-11.8036-23.4099-21.0046-31.2215QC'd by MedChem Express
Inhibitor3548.1339245.146910Single point of activity-2.454.95490.8456-238.64696.5-30 0 0 0 0 0 0 0 0 0 0 0-189.2328-10.2316-11.668-5.7125-6.9939-6.83584.6961-0.7482-3.938510.139967.82411.1988-189.2328QC'd by SIGMA
Inhibitor3548.133962.154810Single point of activity-2.454.0950.6256-60.15482-30 0 0 0 0 0 0 0 0 0 0 0-44.97659.0235-3.711.40378.8489-20.5128-6.788510.687512.245816.8535-8.1934-5.3762-44.9765QC'd by Spectrum Chemical
Inhibitor3548.1339224.207110Single point of activity-2.454.95490.908-226.7071-2.5-30 0 0 0 0 0 0 0 0 0 0 0-188.92260.6552-3.0475-20.07884.3432-7.7208-4.391-10.9476-14.7305-15.72889.415518.4273-188.9226QC'd by Spectrum Chemical
Inactive0004-11.6855-10.3618-6.7493-13.8491-4.0803-8.693.1376-3.5124-6.64858.867923.3566-19.7661-11.6855QC'd by NIEHS
Inactive0-4.454.95490.59135.6731-7.278340 0 0 0 0 0 0 0 0 0 0 027.36422.8347-4.98130.3609-23.9819-6.2913-0.0932-3.8252-15.0975-15.0152-1.0423-10.058427.3642QC'd by NIEHS
Inactive0-5.251.3310.8583-16.27280.540 0 0 0 0 0 0 0 0 0 0 0-15.2273-2.78552.24051.2511-0.30423.2449-5.3421-1.1406-2.134-11.0911-10.1778-14.1452-15.2273QC'd by Microsource
Inactive0-74.95490.4875-12.02527.540 0 0 0 0 0 0 0 0 0 0 0-17.94165.45699.45630.9594-16.173-11.6471-23.6404-23.7713.0401-13.6573-3.3944-2.453-17.9416QC'd by SigmaAldrich
Inactive0-5.22.40640.526320.5918-9.057440 0 0 0 0 0 0 0 0 1 0 1-20.2572.5975-10.44924.0575-21.7145-4.1317-16.8048-9.6264-16.01219.3402-20.985518.4895-20.257QC'd by FLUKA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92uM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of the media in the agonist mode using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonists.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator14.3416104.68542Partial curve; high efficacy-4.843410.9919101.0889-3.59612.10 0 0 0 0 0 0 0 0 0 0 083.8217-5.0801-3.2987-3.4347-0.032-0.5082-3.4679-4.9059-2.01116.607233.435158.618783.8217QC'd by NCI-NPB
Activator25.5034117.202841Partial curve; high efficacy-4.59341.55790.972117.76270.55992.10 0 0 0 0 0 0 0 0 0 0 0103.3007-1.2511-2.7602-6.6167-0.0605-5.67752.2614-0.14648.643812.86419.114350.0412103.3007QC'd by NCI-NPB
Activator31.6228123.593440Partial curve; high efficacy-4.54.95490.9863122.5186-1.07482.10 0 0 0 0 0 0 0 0 0 0 0106.3529-1.8934-3.4581-3.7753-0.6018-3.758-4.229-0.9602-3.3997.09925.555816.7238106.3529QC'd by Analyticon
Activator28.183895.483440Partial curve; partial efficacy-4.551.96730.983596.32520.84182.20 0 0 0 0 0 0 0 0 0 0 072.9863-0.90180.35540.70880.1280.3466-1.38184.17771.71428.226217.96232.910672.9863QC'd by MedChem Express
Activator31.6228133.31840Partial curve; high efficacy-4.51.92820.9932132.865-0.4532.10 0 0 0 0 0 0 0 0 0 0 1-26.5067-1.345-2.46089.2529-0.3764-2.2195-0.666.200620.341762.313997.1543124.4054-26.5067QC'd by USP
Activator1.139282.369826Complete curve; partial efficacy-5.94344.95490.980679.5801-2.78971.20 0 0 0 0 0 0 0 0 0 0 1-8.8595-6.0747-3.93610.8373-3.8801-4.3545-1.7272-0.513610.874178.708390.844968.7426-8.8595QC'd by NCI-NPB
Activator2.27349.889423Complete curve; partial efficacy-5.64341.24750.958544.0109-5.87851.20 0 0 0 0 0 0 0 0 0 0 035.6087-4.4347-7.1334-8.2321-4.2161-5.6276-4.0085-4.3417.381919.996732.016651.531635.6087QC'd by NCI-NPB
Activator4.535247.623422Complete curve; partial efficacy-5.343410.97538.4365-9.18691.20 0 0 0 0 0 0 0 0 0 0 032.3303-6.888-9.4868-10.9846-13.4891-7.3468-8.7296-2.7383-1.26776.575419.047135.092932.3303QC'd by NCI-NPB
Activator16.091648.572421Partial curve; partial efficacy-4.79341.62590.96747.6766-0.89582.20 0 0 0 0 0 0 0 0 0 0 043.41312.86553.37681.2511-0.5359-5.7465-5.372-1.002-0.61711.29410.870830.007143.4131QC'd by NCI-NPB
Activator7.079533.998521Complete curve; partial efficacy-5.151.62660.860433.027-0.97141.20 0 0 0 0 0 0 0 0 0 0 036.6967-1.92390.55984.07911.538-1.549-1.5547-4.55952.667717.157325.347717.240236.6967QC'd by Microsource
Activator14.125445.012521Complete curve; partial efficacy-4.852.33320.950549.01133.99891.20 0 0 0 0 0 0 0 0 0 0 043.90152.575410.42212.13222.62136.6166-9.0E-46.93954.058112.340318.178742.030143.9015QC'd by MedChem Express
Activator11.220240.232521Partial curve; partial efficacy-4.951.41630.934335-5.23252.20 0 0 0 0 0 0 0 0 0 0 033.2046-4.1192-4.572-4.0695-3.3798-5.8283-3.6991-3.6725-6.44379.890318.689517.954533.2046QC'd by Analyticon
Activator14.125458.328721Complete curve; partial efficacy-4.852.53340.979458.89750.56881.20 0 0 0 0 0 0 0 0 0 0 054.63993.51161.77872.62132.4685-2.9488-3.0533-4.10945.3066.893821.233747.459654.6399QC'd by Bio Vision
Activator1040.410521Complete curve; partial efficacy-51.92820.993234.9051-5.50541.20 0 0 0 0 0 0 0 0 0 0 033.2856-5.0152-7.9212-4.8471-4.7554-6.2842-4.5937-3.4997-2.62783.878519.443327.128633.2856QC'd by DC Chemicals
Activator125.892542.598721Partial curve; partial efficacy-3.93.51170.976137.4259-5.17282.20 0 0 0 0 0 0 0 0 0 0 035.6074-5.598-4.4535-4.6006-3.7313-6.9471-4.1018-8.894-6.2272-3.9162-0.216711.113435.6074QC'd by VWR
Activator89.125161.805321Partial curve; partial efficacy-4.052.25260.958363.8512.04572.20 0 0 0 0 0 0 0 0 0 0 056.34353.54612.34033.8269-0.5044-2.87860.16810.48344.07334.340220.973641.969856.3435QC'd by USP
Activator44.668433.361120Partial curve; partial efficacy-4.354.95490.928130.4844-2.87672.20 0 0 0 0 0 0 0 0 0 0 033.48350.7298-3.8211-2.4723-0.4853-2.48731.9269-1.5566-7.3972-6.9654-4.191314.437833.4835QC'd by SIGMA
Activator28.183859.492320Partial curve; partial efficacy-4.552.12110.981559.2264-0.26592.20 0 0 0 0 0 0 0 0 0 0 045.1170.14330.4757-1.1368-1.91440.9583-2.3049-1.3742-0.09592.436810.915519.43245.117QC'd by Specs
Activator22.387250.321220Partial curve; partial efficacy-4.652.33320.967848.961-1.36022.20 0 0 0 0 0 0 0 0 0 0 041.6305-1.0546-0.51781.05653.204-3.1958-2.6962-3.3382-2.3942-3.633510.231422.986341.6305QC'd by NIEHS
Activator22.387266.762120Partial curve; partial efficacy-4.652.04790.966765.0924-1.66972.20 0 0 0 0 0 0 0 0 0 0 053.3263-3.567-2.19723.9071-0.7451-1.2565-1.6762-4.72480.0598-4.496616.107630.04653.3263QC'd by NIEHS
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9muM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92muM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92muM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1muL of the media in the agonist mode using a BioRAPTR FRD and incubated for approximately 24 h at 37 degrees C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for 1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonist.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator10Single point of activity00341.251116.813917.13085.80418.210214.6289.27613.99792.179316.701126.08719.50741.2511QC'd by Axon Medchem
Inhibitor25.118979.49940Partial curve; partial efficacy-4.61.88510.8809-80.4994-1-2.20 0 0 0 0 0 0 0 0 0 0 0-60.9844-8.3599-4.1108-0.3444-11.57673.51984.96689.57164.2331-17.2158-11.7715-39.1274-60.9844QC'd by Timtec
Inhibitor31.622895.56340Partial curve; partial efficacy-4.52.35310.8631-96.0634-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-72.7753-6.8881-3.3208-3.076112.75391.9093-0.79046.82312.6146-7.9331-23.5282-18.0196-72.7753QC'd by Timtec
Inactive00043.91194.76885.58121.6514-8.3499.23334.32514.0356-0.3615-0.20432.6808-0.05673.9119QC'd by NIEHS
Inactive000418.652220.020718.124212.823317.177811.506418.62087.82268.595319.387611.249215.190218.6522QC'd by NIEHS
Inactive0004-11.0235-2.3288-4.9883-2.058-0.38911.1259-8.97082.0241-9.4201-17.1740.791-14.7061-11.0235QC'd by Labotest
Inactive000414.94214.331612.073613.839416.423416.703618.466110.421912.281514.093932.403514.704114.942QC'd by Microsource
Inactive0-4.81.34370.7327-16.04564.540 0 0 0 0 0 0 0 0 0 0 0-11.70460.8383.85191.95357.87343.649512.16163.08212.972-4.30770.1241-9.682-11.7046QC'd by SigmaAldrich
Inactive0-4.653.51170.4081-2.772715.540 0 0 0 0 0 0 0 0 0 0 0-0.643924.925419.07386.06058.42513.415214.919313.794910.669128.759616.52654.2985-0.6439QC'd by FLUKA
Inactive00049.865315.383915.794915.578215.8417.366323.775316.400716.948131.430234.187610.08299.8653QC'd by Timtec
Inactive0-5.44.95490.750319.50.154240 0 0 0 0 0 0 0 0 0 0 016.28962.35072.13075.21067.939-2.1412-1.3331-10.70490.36123.079919.405916.9116.2896QC'd by ASDI
Inactive00046.82660.56726.1190.08513.771-5.7981.34010.590111.032-3.46779.52992.45976.8266QC'd by SigmaAldrich
Inhibitor79.432851.08290Single point of activity-4.13.1320.677-54.5829-3.5-30 0 0 0 0 0 0 0 0 0 0 0-41.3507-6.1955-5.5479-3.6187-6.2729-3.8883-5.9198-10.8577-7.72274.9878-3.69855.5592-41.3507QC'd by SigmaAldrich
Inactive0-4.650.40.5286-34.1016-11.466340 0 0 0 0 0 0 0 0 0 0 0-26.6686-12.5178-8.3053-23.8027-16.0657-16.4067-11.8517-17.1711-20.3545-24.4433-18.1564-26.7513-26.6686QC'd by Enamine
Inactive0-5.34.95490.8647-29.0962-15.214140 0 0 0 0 0 0 0 0 0 0 1-21.5077-17.6173-18.2501-11.8451-14.8537-13.8162-13.1838-16.9815-24.3417-32.9968-29.0139-25.1086-21.5077QC'd by Enamine
Inactive0-5.14.95490.34640-5.205440 0 0 0 0 0 0 0 0 0 0 02.58220.981-6.223-5.7422-5.1579-4.8896-3.0017-9.3378-8.03122.34741.1285-5.59092.5822QC'd by Enamine
Inactive0-60.40.35621.5-11.481840 0 0 0 0 0 0 0 0 0 0 00.1828-6.6154-8.3148-15.81811.639-3.4473-7.9188-3.2712-2.5357-4.00081.1316-1.94090.1828QC'd by SIGMA
Inactive0-4.354.95490.7563-8.091740 0 0 0 0 0 0 0 0 0 0 02.7625-9.96-6.5741-10.0388-9.5144-5.5606-4.3237-10.9098-6.7845-8.0245-8.0118-1.73312.7625QC'd by SIGMA
Inactive0-50.50.61918-18.187840 0 0 0 0 0 0 0 0 0 0 1-16.5209-21.4065-10.9296-12.17-15.9227-14.8775-9.3127-3.8321-10.7718-11.73733.6244-0.1854-16.5209QC'd by LightBiologicals
Inactive0-5.350.40.5288-28.3571-8.718440 0 0 0 0 0 0 0 0 0 0 0-24.4642-11.2992-10.283-18.738-15.1055-5.5987-16.1145-24.2525-18.6306-20.4752-19.2793-22.796-24.4642QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL814496
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 1997
Volume: 7
Issue: 5
First Page: 567
Last Page: 572
DOI: 10.1016/S0960-894X(97)00046-2
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
LD50=6749mg.kg-1Outside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3868903
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2016
Volume: 79
Issue: 9
First Page: 2324
Last Page: 2331
DOI: 10.1021/acs.jnatprod.6b00469
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL984935
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 12
First Page: 1574
Last Page: 1577
DOI: 10.1021/np0302450

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL984944
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293
Standard TypeStandard RelationStandard ValueStandard Units
Activity=100%
Activity=94%
Activity=95.4%
Activity=98.3%
Activity=92.6%
Activity=98.7%
Activity=100%
Activity=96.6%
Activity=97.6%
Activity=95.4%
Activity=96.1%
Activity=95%
Activity=93.1%
Activity=96.1%
Activity=98%
Activity=97.4%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL984943
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293
Standard TypeStandard RelationStandard ValueStandard Units
Activity=82.1%
Activity=73.1%
Activity=76%
Activity=75.4%
Activity=71.9%
Activity=77.1%
Activity=75.3%
Activity=74.2%
Activity=77.4%
Activity=73.7%
Activity=73%
Activity=75.1%
Activity=72.6%
Activity=73.8%
Activity=76.9%
Activity=79%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL984945
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293
Standard TypeStandard RelationStandard ValueStandard Units
IC50=400molar ratio
IC50=280molar ratio
IC50=288molar ratio
IC50=285molar ratio
IC50=275molar ratio
IC50=293molar ratio
IC50=289molar ratio
IC50=286molar ratio
IC50=293molar ratio
IC50=283molar ratio
IC50=280molar ratio
IC50=287molar ratio
IC50=284molar ratio
IC50=287molar ratio
IC50=290molar ratio
IC50=281molar ratio
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL984940
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL984942
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293
Standard TypeStandard RelationStandard ValueStandard Units
Activity=34.2%
Activity=23.5%
Activity=27.9%
Activity=26.8%
Activity=21.7%
Activity=28.5%
Activity=26.4%
Activity=27.5%
Activity=28.9%
Activity=24.6%
Activity=22.7%
Activity=24.9%
Activity=24%
Activity=26.1%
Activity=29.3%
Activity=28.3%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL984941
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 12
First Page: 1582
Last Page: 1585
DOI: 10.1021/np0302293
Standard TypeStandard RelationStandard ValueStandard Units
Activity=8.6%
Activity=0%
Activity=1.2%
Activity=2.1%
Activity=0%
Activity=3.6%
Activity=2.3%
Activity=0%
Activity=2.3%
Activity=0%
Activity=0%
Activity=0%
Activity=0%
Activity=2%
Activity=2.2%
Activity=0%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: APP-Toga-CHIKV-nsP2-f2-f9
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1.Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2.Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3.The plate was incubated at room temperature (protected from light) for 15 min
4.Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5.After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1.Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2.For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001943322 uMActivity at 0.0004169086 uMActivity at 0.0006184621 uMActivity at 0.00125 uMActivity at 0.00187 uMActivity at 0.00374 uMActivity at 0.00620 uMActivity at 0.011 uMActivity at 0.019 uMActivity at 0.034 uMActivity at 0.057 uMActivity at 0.103 uMActivity at 0.171 uMActivity at 0.309 uMActivity at 0.513 uMActivity at 0.958 uMActivity at 1.860 uMActivity at 2.874 uMActivity at 5.579 uMActivity at 8.623 uMActivity at 16.74 uMActivity at 25.51 uMActivity at 50.00 uMActivity at 83.33 uMActivity at 250.0 uMCompound QC
Inactive0004-3.9794-0.1198-7.062-11.5818-9.1944-3.8178-1.1441-5.6132-4.9511-5.5587-6.1624-3.9794QC'd by ACC
Inactive0-8.19790.30.608993140 0 0 0 0 0 0 0 0 0 010.172223.924224.655819.16521.660312.625318.76147.470919.892413.78158.189910.1722QC'd by Pharmaron
Activator8.955243.2190Partial curve; partial efficacy; poor fit-5.04791.3310.924736.0289-7.19012.40 0 0 0 0 0 0 0 0 0 029.4662-7.0776-6.47-9.2528-8.4641-9.2431-10.5751-5.22763.4595-2.881113.357829.4662QC'd by SIGMA
Inactive0-5.24790.40.3288-23.185-14.612940 0 0 0 0 0 0 0 0 0 0-20.7246-17.2155-15.3616-10.5108-18.084-14.0374-14.4678-15.7745-20.1988-20.9875-15.4123-20.7246QC'd by SIGMA
Activator7.113361.86540Partial curve; partial efficacy-5.14791.22210.985957.5474-4.3182.20 0 0 0 0 0 0 0 0 0 047.1053-2.7798-7.765-4.3513-5.9053-6.2870.5579-3.14590.608510.477728.702947.1053QC'd by Microsource
Inactive0-4.99790.60.627332840 0 0 0 0 0 0 0 0 0 026.108311.84129.28933.73345.70737.117815.20258.219319.316410.390817.592726.1083QC'd by Sequoia
Inactive0-5.74792.84730.9367-8.457912.540 0 0 0 0 0 0 0 0 0 0-9.131617.489614.59513.712112.150311.963210.01038.353810.3971-3.7628-7.349-9.1316QC'd by SIGMA
Inactive0-6.19790.60.544812-8.077540 0 0 0 0 0 0 0 0 0 1-5.6385-0.4717-21.3146-4.9131-1.5492-3.8745-4.9958-1.24894.18266.38268.2921-5.6385QC'd by Sytravon
Activator0.2832102.74350Partial curve; high efficacy-6.54791.78850.9885108.743562.10 0 0 0 0 0 0 0 1 1 1-95.91469.03367.02688.00912.495715.738721.831160.2571100.6884-22.8645-96.4497-95.9146QC'd by Sytravon
Inactive0-7.24790.50.705816240 0 0 0 0 0 0 0 0 0 17.40721.81285.59638.76350.293110.41188.75414.272511.851314.558914.81967.4072QC'd by Sytravon
Inactive0-6.09792.33320.5919-23.922-17.424240 0 0 0 0 0 0 0 0 0 0-24.9757-19.9067-14.6333-19.3926-16.8611-18.3099-13.2702-19.0908-20.4306-26.6017-20.1209-24.9757QC'd by Selleck
Activator2.523937.05290Partial curve; partial efficacy-5.59791.10.889926-11.05292.20 0 0 0 0 0 0 0 0 0 1-9.5741-14.2107-9.4787-6.7894-9.9383-13.1553-12.9138-4.80511.47322.279422.5785-9.5741QC'd by MedChem Express
Inactive0004-13.8524-9.282-5.697-4.2734-5.2179-3.3835-12.0959-4.84792.5228-14.939-6.0319-13.8524QC'd by Analyticon
Inactive0-5.65921.71370.8905-25.7583-14.342340 0 0 0 0 0 0 0 0 0 0-25.6319-16.1698-13.0793-14.8397-14.8495-13.9732-15.8115-12.3686-13.1319-19.083-21.7489-25.6319QC'd by Analyticon
Inactive0-7.50924.95490.619722.51340 0 0 0 0 0 0 0 0 0 19.598319.80839.92213.466214.199812.236423.007719.385826.190324.596918.43779.5983QC'd by Analyticon
Inactive0-7.84791.82650.8442-13.182-2.534240 0 0 0 0 0 0 0 0 0 0-17.235-1.6952-2.6747-4.1488-5.954-12.7639-12.1446-11.8915-10.8594-10.5634-16.1912-17.235QC'd by Analyticon
Inactive0004-17.7491-20.0995-21.9281-15.9595-15.8056-19.8756-17.2058-20.6448-14.277-20.5571-18.9876-17.7491QC'd by MedChem Express
Inactive0-6.44790.40.90323818.540 0 0 0 0 0 0 0 1 1 11.046919.221819.961723.310422.263624.416123.653128.414430.579620.197211.55121.0469QC'd by MedChem Express
Inactive0-5.25922.47290.682-17.827616.540 0 0 0 0 0 0 0 0 0 0-13.815121.03812.38782.682312.39217.096620.565119.339528.679215.0074.7718-13.8151QC'd by Analyticon
Inactive0-5.34791.10.676-42.4703-22.027640 0 0 0 0 0 0 0 0 0 0-37.2303-24.1889-23.1958-17.9964-27.2599-16.273-18.493-30.4886-23.3633-27.5267-38.9926-37.2303QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f3_f16
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Reagent; 3 uL; Papain in assay buffer.
1b; Reagent; 3uL; Assay buffer
2; Compound; 17 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 1 uL; Z-FR-AMC in assay buffer.
5; Incubation; 15 sec, 271g; centrifugation.
6; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
7; Incubation; 10 min; room temperature
8; Detection; Fluorescence; time 10; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1a. Medium-binding black solid-bottom Greiner plates (cat. 789176-F). Dispense 3 uL of 1.33X papain in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1, 2, 5-48 via Wako/Kalypsys dispenser. Papain (cat. P4762, Sigma) was dispensed to produce 5 nM final concentration. Enzyme solution kept on ice during experiment. Prepare papain as 50% glycerol (v/v) at final concentration of 10 mg/mL (427 uM, 100 U/mL). Sources: microplates (Greiner 789176-F), papain (Sigma P4762), sodium acetate (Bioworld 40120009-2), cysteine (Sigma 861677), Tween-20 (Sigma P1379), water (GIBCO 10977-015; Gibco).
1b. Dispense 3 uL of assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 3 and 4 via Wako/Kalypsys dispenser. Assay buffer solution kept on ice during experiment.
2. Compound addition by single pin transfer (17 nL) using Wako pintool. Compound solutions in source plate: 169 nM to 10 mM DMSO stock solutions. Final concentrations: 0.664 nM to 39.2 uM, respectively. Final DMSO concentration: 0.5% (v/v).
3. RT incubation. Kalypsys lids used as microplate coverings. Protected from light.
4. Dispense 1 uL of 4x substrate mixture in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1-48 via Wako/Kalypsys dispenser. Z-FR-AMC substrate was dispensed to produce 2 uM final concentration. Substrate solution kept on ice during experiment. Prepare Z-FR-AMC as 32.1 mM stock solution in DMSO. Source: Z-FR-AMC (HCl salt) (Bachem I-1160).
5. Centrifugation step to remove bubbles.
6. ViewLux microplate reader (PerkinElmer, Waltham, MA). Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.
7. RT incubation. Incubation time 10 min.
8. ViewLux microplate reader. Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.5901109.960786Complete curve; high efficacy-5.58671.210.9897-108.96071-1.10 0 0 0 0 0 0 0 0 0 0-111.41171.55560.16860.5912-2.32080.5546-1.7222-9.4735-49.3194-78.617-90.0782-111.4117QC'd by Tocris
Inhibitor2.057490.645386Complete curve; high efficacy-5.686710.9996-95.4556-4.8103-1.10 0 0 0 0 0 0 0 0 0 0-91.4326-5.6107-5.4875-5.5173-5.2586-8.3832-11.5147-25.8607-48.4417-70.9035-84.9963-91.4326QC'd by SIGMA
Inhibitor2.590198.49686Complete curve; high efficacy-5.58674.0950.9994-101.9353-3.4393-1.10 0 0 0 0 0 0 0 0 0 0-102.3447-3.0022-2.6536-4.2124-2.3934-2.0327-2.9719-4.1726-25.8834-97.2501-101.4914-102.3447QC'd by NCGCChem
Inhibitor2.5901105.413785Complete curve; high efficacy-5.58670.80.9976-100.41375-1.10 0 0 0 0 0 0 0 0 0 0-90.95457.53544.46353.58863.2188-2.4359-10.3973-17.5405-39.749-63.8592-82.3674-90.9545QC'd by Tocris
Inhibitor12.98185.533582Complete curve; high efficacy-4.88674.95490.9967-87.5434-2.0099-1.10 0 0 0 0 0 0 0 0 0 0-85.325-1.8297-3.5602-3.91-1.0422-1.2527-1.4075-3.9675-0.4249-0.4411-70.6158-85.325QC'd by Sytravon
Inhibitor4.10593.343644Partial curve; partial efficacy-5.38670.70.9979-89.84363.5-2.20 0 0 0 0 0 0 0 0 0 0-77.65374.60332.57411.55570.6086-2.727-5.8785-14.7051-32.247-48.4602-62.0742-77.6537QC'd by APAC
Inhibitor9.189981.712442Partial curve; partial efficacy-5.03671.10.9987-84.3066-2.5942-2.20 0 0 0 0 0 0 0 0 0 0-72.9596-2.0933-3.4233-3.1998-2.8829-2.6472-1.7452-7.9092-14.2316-31.7647-56.8608-72.9596QC'd by Glixx
Inhibitor18.336272.984941Partial curve; partial efficacy-4.73672.04790.956-75.9849-3-2.20 0 0 0 0 0 0 0 0 0 0-70.3563-1.7343-12.6104-4.1714.03140.7429-2.4048-1.3619-5.566-12.2596-31.5981-70.3563QC'd by Princeton
Inhibitor18.336273.450741Partial curve; partial efficacy-4.73671.53860.9946-82.1193-8.6686-2.20 0 0 0 0 0 0 0 0 0 0-72.0345-7.7697-8.6785-9.0916-9.479-8.3494-7.2238-9.8284-10.1223-21.6905-41.8484-72.0345QC'd by Microsource
Inhibitor23.083988.658741Partial curve; high efficacy-4.63672.40640.9832-92.503-3.8444-2.10 0 0 0 0 0 0 0 0 0 0-90.6892-3.5026-2.9812-3.2189-4.6998-1.9536-5.3552-5.0547-4.555-8.1241-29.8904-90.6892QC'd by NCGCChem
Inhibitor2.906155.229123Complete curve; partial efficacy-5.53670.70.9915-52.22913-1.20 0 0 0 0 0 0 0 0 0 0-45.24942.53842.22822.66160.2019-1.9921-2.393-10.3912-22.8963-27.6273-41.5174-45.2494QC'd by MedChem Express
Inhibitor16.342181.36321Partial curve; partial efficacy-4.78671.28760.9793-77.8633.5-2.20 0 0 0 0 0 0 0 0 0 0-64.88584.62066.61036.34755.43191.9795-3.94211.1208-2.7854-12.2731-33.9047-64.8858QC'd by Microsource
Inhibitor18.336258.528921Partial curve; partial efficacy-4.73671.22210.9689-56.02892.5-2.20 0 0 0 0 0 0 0 0 0 0-46.69084.23963.60586.59553.80761.7487-1.2158-0.5062-1.333-10.3615-20.7839-46.6908QC'd by Microsource
Inhibitor18.336263.657421Partial curve; partial efficacy-4.73671.10.931-61.15742.5-2.20 0 0 0 0 0 0 0 0 0 0-50.96456.82263.13523.21093.8242.1658-3.03871.5869-9.9978-10.7579-20.2792-50.9645QC'd by MedChem Express
Inhibitor16.017653.680221Partial curve; partial efficacy-4.79541.10.9332-59.7413-6.061-2.20 0 0 0 0 0 0 0 0 0 0-47.4137-9.9147-8.0265-4.9002-7.74-1.7175-9.128-10.8321-13.0781-14.6739-24.7757-47.4137QC'd by Analyticon
Inhibitor11.273938.61321Partial curve; partial efficacy-4.94791.3310.9367-43.2673-4.6543-2.20 0 0 0 0 0 0 0 0 0 0-36.0561-3.0892-0.9619-5.6766-4.829-2.5548-6.7305-9.0092-6.7736-9.551-16.7432-36.0561QC'd by Analyticon
Inhibitor14.564967.495921Partial curve; partial efficacy-4.83671.10.983-68.9959-1.5-2.20 0 0 0 0 0 0 0 0 0 0-54.16350.8818-0.2331-1.50670.5982-1.1965-4.6761-8.0636-7.7637-15.5972-40.2452-54.1635QC'd by Glixx
Inhibitor16.342164.033421Partial curve; partial efficacy-4.78671.24750.987-60.03344-2.20 0 0 0 0 0 0 0 0 0 0-50.02786.60443.85072.66763.5393.9191.76213.45141.0614-12.3878-25.4689-50.0278QC'd by SIGMA
Inhibitor18.336270.455621Partial curve; partial efficacy-4.73671.62590.9803-68.95561.5-2.20 0 0 0 0 0 0 0 0 0 0-60.48735.82951.2932.17034.24110.8209-1.49341.094-2.4894-11.3309-27.749-60.4873QC'd by SIGMA
Inhibitor18.336252.926821Partial curve; partial efficacy-4.73671.41630.9896-55.8043-2.8775-2.20 0 0 0 0 0 0 0 0 0 0-46.5035-5.734-1.7587-1.7696-3.3881-1.8874-1.1479-3.8743-3.938-12.2677-26.0707-46.5035QC'd by Scientific Exchange
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide.
5; Detection; Fluorescence; time 0, ViewLux microplate reader (PerkinElmer) 525 nm excitation, 598/25 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two microliter of NS3-4A HCV enzyme solution (5 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nanoliter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counter-screen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM substrate (Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide) in assay buffer (for NS3-4A assay) was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with Tamara fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008333407 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00748 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.115 uMActivity at 0.206 uMActivity at 0.344 uMActivity at 0.619 uMActivity at 1.033 uMActivity at 1.912 uMActivity at 3.719 uMActivity at 5.737 uMActivity at 11.16 uMActivity at 17.21 uMActivity at 33.48 uMActivity at 50.94 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.25992.105390Complete curve; high efficacy-6.58673.990.9964-92.10530-1.10 0 0 0 0 0 0 0 0 1 1000000-26.9057-94.1772-91.9507-86.4857-67.71240QC'd by GVK
Inhibitor0.205796.846490Complete curve; high efficacy-6.68670.50.9869-93.84643-1.10 0 0 0 0 0 0 0 0 0 0-88.36761.1189-13.0457-11.9936-16.2335-34.002-49.7919-58.5074-65.2049-76.2052-87.4254-88.3676QC'd by Cayman
Inhibitor0.81998.080488Complete curve; high efficacy-6.08674.95490.9998-98.08040-1.10 0 0 0 0 0 0 0 0 0 0-99.071100000-1.3807-18.4263-95.594-97.8277-98.7603-99.0711QC'd by SigmaAldrich
Inhibitor1.833690.267186Complete curve; high efficacy-5.736710.9788-90.7671-0.5-1.10 0 0 0 0 0 0 0 0 0 0-90.0467-11.97791.8615-1.11490.31450.4826-1.9658-28.8777-45.643-65.5697-80.455-90.0467QC'd by Sytravon
Inhibitor1.634297.729886Complete curve; high efficacy-5.78671.1110.9949-91.72986-1.10 0 0 0 0 0 0 0 0 0 0-91.54674.74716.6915.74934.61264.6496-4.2191-15.4016-52.1541-67.1067-83.4886-91.5467QC'd by Sytravon
Inhibitor1.634280.443285Complete curve; high efficacy-5.78671.41630.9844-82.9432-2.5-1.10 0 0 0 0 0 0 0 0 0 0-86.94260.0017-2.7057-0.96350.2371-10.9118-7.4073-13.1382-51.7572-66.8444-76.6984-86.9426QC'd by Sytravon
Inhibitor11.5693142.296983Complete curve; high efficacy-4.93674.95490.9843-146.2969-4-1.10 0 0 0 0 0 0 0 0 0 0-145.1358-11.1377-4.9584-14.1999-14.9851-11.52250000-127.65-145.1358QC'd by BOC Sciences
Inhibitor2.982882.380383Complete curve; high efficacy-5.52541.1110.9956-67.380315-1.10 0 0 0 0 0 0 0 0 0 0-66.408515.731216.408516.690113.75649.84876.8460.9994-27.4034-46.3695-59.0006-66.4085QC'd by ChemRoutes
Inhibitor5.167882.670583Complete curve; high efficacy-5.28671.69240.9917-84.1705-1.5-1.10 0 0 0 0 0 0 0 0 0 0-84.00242.33990.0403-2.9808-0.1304-2.852-3.4511-8.3788-9.4642-47.6561-71.3126-84.0024QC'd by ChemRoutes
Inhibitor0.579874.517767Complete curve; partial efficacy-6.23671.78850.9905-84.7108-10.1932-1.20 0 0 0 0 0 0 0 0 0 0-85.7922-6.411-13.187-13.2655-8.1855-13.3519-15.8017-54.0083-71.981-81.2068-87.6924-85.7922QC'd by Pharmaron
Inhibitor4.10572.3264Complete curve; partial efficacy-5.38671.50950.9933-89.4126-17.0927-1.20 0 0 0 0 0 0 0 0 0 0-90.3158-20.231-13.4106-18.193-17.5607-16.7098-16.5249-21.8958-32.2241-62.637-77.852-90.3158QC'd by Sytravon
Inhibitor10.311271.125562Complete curve; partial efficacy-4.98672.40640.9806-86.3626-15.2371-1.20 0 0 0 0 0 0 0 0 0 0-85.1702-13.7671-12.9532-14.248-25.2859-13.461-15.2839-12.6976-15.193-27.0044-68.8421-85.1702QC'd by Analyticon
Inhibitor9.189967.032862Complete curve; partial efficacy-5.03671.82650.9939-76.8664-9.8336-1.20 0 0 0 0 0 0 0 0 0 0-70.7322-10.7907-8.6988-8.6114-9.0149-11.4364-9.2773-12.7817-14.9845-27.5022-61.3355-70.7322QC'd by Chemdiv
Inhibitor8.1905106.357343Partial curve; high efficacy-5.08670.50.9661-114.4951-8.1378-2.10 0 0 0 0 0 0 0 0 0 0-86.7387-3.4482-13.2288-17.8624-15.8022-16.7275-16.6046-30.643-44.1175-47.0452-75.7003-86.7387QC'd by BIOMOL
Inhibitor11.5693128.704843Partial curve; high efficacy-4.93673.29750.9933-121.20487.5-2.10 0 0 0 0 0 0 0 0 0 0-121.6916-2.99137.44749.60127.73788.80399.956610.49748.9646-2.3207-89.0932-121.6916QC'd by NCGCChem
Inhibitor12.98167.215642Partial curve; partial efficacy-4.88671.10.9972-84.7948-17.5792-2.20 0 0 0 0 0 0 0 0 0 0-72.5718-16.8006-15.8993-18.304-17.8466-17.1874-19.286-19.9586-25.6491-34.807-56.3917-72.5718QC'd by Analyticon
Inhibitor16.3421132.313242Partial curve; high efficacy-4.78671.28760.9936-133.8132-1.5-2.10 0 0 0 0 0 0 0 0 0 0-111.511-1.0773-3.27710.19161.699-3.4092-5.8988-5.8666-5.6959-30.4121-64.6714-111.511QC'd by Life Chemicals
Inhibitor20.573598.567741Partial curve; high efficacy-4.68673.06540.9967-98.56770-2.10 0 0 0 0 0 0 0 0 0 0-96.6351.366200000000-36.802-96.635QC'd by APExBIO
Inhibitor23.0839122.554341Partial curve; high efficacy-4.63674.0950.8771-108.817213.7371-2.10 0 0 0 0 0 0 0 0 0 0-101.695-5.92085.54383.16447.27436.362713.609223.729537.428332.861-14.4157-101.695QC'd by NCGCChem
Inhibitor0.650655.936625Complete curve; partial efficacy-6.18672.72020.9428-55.43660.5-1.20 0 0 0 0 0 0 0 0 0 0-56.768000000-22.2431-60.7149-64.5173-39.0284-56.768QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-full-length
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL NSP2 full length enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008233323 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.351 uMActivity at 0.618 uMActivity at 1.053 uMActivity at 1.927 uMActivity at 3.720 uMActivity at 5.782 uMActivity at 11.16 uMActivity at 17.34 uMActivity at 33.48 uMActivity at 50.65 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.0311106.093288Complete curve; high efficacy-5.986710.99-101.59324.5-1.10 0 0 0 0 0 0 0 0 0 0-98.4439.69810.004410.7127-6.9536-2.2974-11.3519-36.1756-62.6061-84.2015-97.0708-98.443QC'd by SigmaAldrich
Inhibitor0.919111.417488Complete curve; high efficacy-6.03671.10.9849-97.917413.5-1.10 0 0 0 0 0 0 0 0 0 0-96.36467.404918.91937.176321.7697-0.27442.4876-34.3663-61.0045-84.521-92.9929-96.3646QC'd by Selleck
Inhibitor1.4565108.77387Complete curve; high efficacy-5.83670.90.9912-101.2737.5-1.10 0 0 0 0 0 0 0 0 0 0-98.132810.07855.0453-2.210212.6454-0.7438-8.1305-26.4248-53.3465-74.5675-90.2675-98.1328QC'd by Selleck
Inhibitor1.2981107.823587Complete curve; high efficacy-5.886710.9927-101.32356.5-1.10 0 0 0 0 0 0 0 0 0 0-97.05321.48227.484311.22584.259-2.139-4.1769-31.5222-52.5312-85.691-92.9687-97.0532QC'd by Tocris
Inhibitor1.156992.80487Complete curve; high efficacy-5.93671.210.976-96.804-4-1.10 0 0 0 0 0 0 0 0 0 0-96.03577.5254-14.9467-7.974-2.01-12.1318-6.5988-36.504-61.4538-83.187-95.332-96.0357QC'd by SIGMA
Inhibitor1.456595.066587Complete curve; high efficacy-5.836710.9926-99.0665-4-1.10 0 0 1 0 0 0 0 0 0 0-95.99472.226-3.6974-10.351930.2584-11.8423-14.0904-31.1299-59.4844-78.33-91.9831-95.9947QC'd by NCGCChem
Inhibitor1.8336110.365186Complete curve; high efficacy-5.73671.24750.9945-99.365111-1.10 0 0 0 0 0 0 0 0 0 0-94.995815.797610.24626.95079.791910.4877.1488-16.8798-40.2744-77.7593-95.7275-94.9958QC'd by Microsource
Inhibitor2.0574107.49186Complete curve; high efficacy-5.68671.22210.9783-93.49114-1.10 0 0 0 0 0 0 0 0 0 0-92.234113.63262.353916.684313.807818.062618.6688-16.6338-34.2006-66.3978-87.0605-92.2341QC'd by Sytravon
Inhibitor2.0574110.033386Complete curve; high efficacy-5.68670.90.9865-101.53338.5-1.10 0 0 0 0 0 0 0 0 0 0-94.53752.57514.84352.581314.72980.6931-8.9626-15.325-43.8815-68.5449-89.3213-94.5375QC'd by Sytravon
Inhibitor1.4193104.591986Complete curve; high efficacy-5.84791.22210.9804-95.59199-1.10 0 0 0 0 0 0 0 0 0 0-91.56313.338212.1183.45719.685216.62987.975-15.319-22.3855-65.6932-86.2038-91.5631QC'd by Microsource
Inhibitor2.906193.574185Complete curve; high efficacy-5.53671.10.9812-95.0741-1.5-1.10 0 0 0 0 0 0 0 0 0 0-87.5452-10.254-2.4392-6.9481-0.21635.7988-1.9135-16.6748-36.4819-65.1695-80.976-87.5452QC'd by Sytravon
Inhibitor3.260799.032985Complete curve; high efficacy-5.48671.34430.9632-93.53295.5-1.10 0 0 0 0 0 0 0 0 0 0-91.6989-3.2822-3.856916.56124.99049.207314.3935-14.7708-21.951-60.88-83.1689-91.6989QC'd by Sytravon
Inhibitor4.10587.564284Complete curve; high efficacy-5.38671.34430.9761-91.5642-4-1.10 0 0 0 0 0 0 0 0 0 0-86.7085-6.111-5.8563-10.9621-8.20018.6265-8.333-8.9422-26.9277-56.1051-82.3696-86.7085QC'd by Sytravon
Inhibitor4.10594.757984Complete curve; high efficacy-5.38672.53340.9206-89.75795-1.10 0 0 0 0 0 0 0 0 0 0-94.487-2.0682-6.881818.97199.079426.6747-3.0833-13.5252-0.671-59.3912-82.4679-94.487QC'd by Sytravon
Inhibitor5.1678111.309384Complete curve; high efficacy-5.28671.1110.972-99.809311.5-1.10 0 0 0 0 0 0 0 0 0 0-90.123318.46670.454721.0592.25616.804310.3614-3.5838-12.6269-47.0769-77.3938-90.1233QC'd by Sytravon
Inhibitor4.7274110.237784Complete curve; high efficacy-5.32540.90.9989-105.23775-1.10 0 0 0 0 0 0 0 0 0 0-95.3244.46492.41734.84984.69613.5345-3.5636-16.4321-36.8529-65.4142-85.8945-95.324QC'd by ChemRoutes
Inhibitor6.6764102.715483Complete curve; high efficacy-5.175510.9925-85.715417-1.10 0 0 0 0 0 0 0 0 0 0-78.274524.400614.971411.383313.800814.663512.97462.3962-20.6265-48.4262-68.5588-78.2745QC'd by SigmaAldrich
Inhibitor6.505996.411583Complete curve; high efficacy-5.18671.98870.985-81.911514.5-1.10 0 0 0 0 0 0 0 0 0 0-82.35358.798114.34957.773819.733320.147916.82811.749112.1698-29.6807-65.7541-82.3535QC'd by Microsource
Inhibitor9.189994.261583Complete curve; high efficacy-5.03674.95490.984-98.2615-4-1.10 0 1 0 0 0 0 0 0 0 0-96.33483.9892-13.509951.244-3.2532-4.06541.2359-5.945-8.4138-9.4606-95.1238-96.3348QC'd by SIGMA
Inhibitor7.299894.557283Complete curve; high efficacy-5.13671.66040.9244-98.5572-4-1.10 0 0 0 0 0 0 0 0 0 0-91.766513.2607-14.95846.5402-15.1959-12.7095-5.0389-9.5867-19.5062-34.0351-85.2014-91.7665QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f18-cell-based
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Cell Transfection; Lipofectamine 2000.
1b; Cell; 4 uL; Aurora 1536-well, white, tissue culture plate.
2; Incubation; 4 hr; 37C, 5% CO2, 95% humidity.
3; Compound; 20 nL; Echo 650 Liquid Handler.
4; Incubation; overnight; 37C, 55 CO2, 95% humidity.
5; Reagent; 4 uL; Nano-Glo Luciferase assay system.
6; Centrifugation; 2 sec.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to sequence numbers above).
1a. For the 1,536-well assay, cells were transfected in T75 flasks using a reverse transfection procedure, where 9 mL of complexes containing 45 uL Lipofectamine 2000 (ThermoFisher Scientific), 20 ug nsP2 plasmid, and 0.2 ug Nluc reporter plasmid, were combined with 10 mL of HEK293T cell suspension (1x10^6 cells/mL, 10 million cells total). Complexes containing Transfection Carrier DNA (Promega) and Nluc reporter plasmid (also at 1:100 ratio) were used as a high-signal control. After 24h, cells were harvested by trypsinization and resuspended at a density of 1x10^6 cells/ml.
1b. Cells were dispensed (4 uL cell/well) into 1,536-well white plates (Aurora, cyclic olefin polymer, cat# EWB041000A) using a Multidrop Combi.
2-4. After 4 hours, compounds (20 nL) were subsequently pinned using an Echo 650 Series Liquid Handlers and incubated overnight at 37C.
5. Nano-Glo (Promega) reagent was added (4 uL /well) according to the manufacturer's recommendations.
6-7. The Plates were centrifuged and analyzed for luminescence intensity using a ViewLux reader.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008286089 uMActivity at 0.00124 uMActivity at 0.00248 uMActivity at 0.00373 uMActivity at 0.00744 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.040 uMActivity at 0.069 uMActivity at 0.111 uMActivity at 0.206 uMActivity at 0.353 uMActivity at 0.624 uMActivity at 1.115 uMActivity at 1.930 uMActivity at 3.480 uMActivity at 5.807 uMActivity at 11.67 uMActivity at 17.60 uMActivity at 33.48 uMActivity at 51.06 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.412597.022587Complete curve; high efficacy-5.850.90.957-104.5706-7.5482-1.10 0 0 0 0 0 0 0 0 0 0-97.2822-11.2901-18.8772-11.6693-43.4765-44.248-44.8652-79.0266-84.1272-97.3439-97.9126-97.2822QC'd by GVK
Inhibitor1.4565126.346487Complete curve; high efficacy-5.83671.69240.9931-110.846415.5-1.11 0 0 0 0 0 0 0 0 0 0-107.409337.871713.682213.064213.776920.336416.8573-14.9483-55.8355-105.909-107.0903-107.4093QC'd by Chemdiv
Inhibitor0.4606100.414987Complete curve; high efficacy-6.33674.95490.928-79.296321.1186-1.10 0 0 0 0 0 0 0 0 0 0-80.69525.98363.899320.805713.096232.323152.0621-68.7904-68.3183-79.5773-81.684-80.6952QC'd by Chemdiv
Inhibitor2.0574127.04387Complete curve; high efficacy-5.68671.46410.9422-115.04312-1.10 0 0 0 0 0 0 0 0 0 0-108.296627.274827.23495.92651.1464-4.6804-0.5882-17.3408-29.4928-107.7134-107.9427-108.2966QC'd by NCGCChem
Inhibitor2.5901129.453786Complete curve; high efficacy-5.58671.82650.9531-115.953713.5-1.10 0 0 0 0 0 0 0 0 0 0-106.89125.29617.7047-2.168223.67114.5545-10.467319.514-32.1645-97.9389-107.1103-106.891QC'd by Sytravon
Inhibitor2.590197.869686Complete curve; high efficacy-5.58674.50450.9733-101.8696-4-1.10 0 0 0 0 0 0 0 0 0 0-102.3291-9.4766-13.236-4.3824-14.7087-2.633912.43521.8642-20.9241-97.3951-102.8986-102.3291QC'd by Chemdiv
Inhibitor2.0574116.348186Complete curve; high efficacy-5.68672.25260.9818-104.848111.5-1.10 0 0 0 0 0 0 0 0 0 0-99.988917.87645.414518.601721.38231.31256.6781-1.5616-36.6071-101.7374-101.5594-99.9889QC'd by NCGCChem
Inhibitor4.6058118.776985Complete curve; high efficacy-5.33673.990.9688-109.27699.5-1.10 0 0 0 0 0 0 0 0 0 0-107.319627.49919.9838-0.73770.5034-4.102211.125217.550211.1202-74.9358-107.3595-107.3196QC'd by Sytravon
Inhibitor5.6234109.163984Complete curve; high efficacy-5.251.88510.9652-105.16394-1.10 0 0 0 0 0 0 0 0 0 0-96.78411.62524.71273.4254-4.5143-4.9331-20.5877-16.0337-50.9533-98.0537-98.468-96.784QC'd by DC Chemicals
Inhibitor7.2998107.495784Complete curve; high efficacy-5.13671.22210.9783-111.4957-4-1.10 0 0 0 0 0 0 0 0 0 0-103.2367-13.2538-0.02672.0065-5.81943.6661-9.6857-15.95-22.7304-46.7644-84.8842-103.2367QC'd by NCGCChem
Inhibitor11.569397.536882Complete curve; high efficacy-4.93674.95490.9485-101.0368-3.5-1.10 0 0 0 0 0 0 0 0 0 0-99.6418-12.43523.0387-14.6153-12.22614.35122.43818.8048-13.72541.3125-89.3911-99.6418QC'd by Chembridge
Inhibitor11.569398.82882Complete curve; high efficacy-4.93674.50450.9121-102.828-4-1.10 0 0 0 0 0 0 0 0 0 0-102.6227-1.8731-15.5763-26.5166-12.5464-17.5339-1.8642-10.07279.9126-6.6647-86.3836-102.6227QC'd by Vitas
Inhibitor23.083979.475841Partial curve; partial efficacy-4.63674.0950.8235-82.9758-3.5-2.20 0 0 0 0 0 0 0 0 0 0-77.0049-11.7145-10.8602-14.62426.090818.6951-3.1322-12.0125-9.70796.7448-19.7584-77.0049QC'd by NCGCChem
Inhibitor20.573599.804841Partial curve; high efficacy-4.68671.71370.8734-98.30481.5-2.10 0 0 0 0 0 0 0 0 0 0-86.23230.8676-9.5389-7.5191.041115.211411.478716.8843-15.6741-12.7422-33.4839-86.2323QC'd by NCGCChem
Inhibitor20.573583.186341Partial curve; partial efficacy-4.68672.72020.8668-73.68639.5-2.20 0 0 0 0 0 0 0 0 0 0-73.338822.12982.3847-10.384210.49990.102319.660520.92419.88146.9673-17.4182-73.3388QC'd by NCGCChem
Inhibitor18.3362121.834541Partial curve; high efficacy-4.73672.78680.9485-108.334513.5-2.11 0 0 0 0 0 0 0 0 0 0-101.2702-23.8516-2.073330.62758.119614.1175.098717.920920.43917.8615-40.4645-101.2702QC'd by Chembridge
Inhibitor20.573584.41341Partial curve; partial efficacy-4.68672.33320.892-78.4136-2.20 0 0 0 0 0 0 0 0 0 0-72.8494-2.82072.460317.213514.93561.846412.4664-6.695915.6163-7.5679-24.6257-72.8494QC'd by NCGCChem
Inhibitor20.573592.825941Partial curve; high efficacy-4.68674.0950.9171-78.325914.5-2.10 0 0 0 0 0 0 0 0 0 0-73.226310.5264-3.15115.104918.850515.991227.25478.379713.951423.9589-13.1452-73.2263QC'd by NCGCChem
Inhibitor20.573583.187141Partial curve; high efficacy-4.68673.1320.8423-62.127821.0593-2.10 0 0 0 0 0 0 0 0 0 0-64.6929-2.536422.293214.267618.280420.7337.992716.454438.665223.812-8.8563-64.6929QC'd by NCGCChem
Inhibitor0.579833.910523Complete curve; partial efficacy-6.23674.44950.9281-32.91051-1.20 0 0 0 0 0 0 0 0 0 0-32.7721-6.1106-3.99926.126-3.02061.918710.2023-19.0021-31.9399-32.7413-33.1189-32.7721QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f5_f16-endo
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM endogenous NS2/3 peptide substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of endogenous NS2/3 peptide substrate (peptide 3: TMR-DELRLDRAGC/APSYR-K-QSY7; 2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.81987.038587Complete curve; high efficacy-6.08671.34430.9961-84.53852.5-1.10 0 0 0 0 0 0 0 0 0 0-87.51391.114002.97934.2662-7.9466-33.2435-61.766-76.6432-81.3334-87.5139QC'd by SIGMA
Inhibitor1.634289.661386Complete curve; high efficacy-5.78670.80.9918-94.197-4.5357-1.10 0 0 0 0 0 0 0 0 0 0-90.227-2.5297-3.4679-9.635-7.1695-14.792-15.9048-29.4095-56.4408-69.3217-79.2648-90.227QC'd by APAC
Inhibitor1.833694.496186Complete curve; high efficacy-5.73671.86170.9989-94.9961-0.5-1.10 0 0 0 0 0 0 0 0 0 0-95.3776-1.3502-0.2066-2.42582.7774-1.6197-2.0908-11.2497-47.9814-82.942-94.0736-95.3776QC'd by Selleck
Inhibitor1.833698.758986Complete curve; high efficacy-5.73671.80790.9926-96.25892.5-1.10 0 0 0 0 0 0 0 0 0 0-96.17612.1633-3.0162-1.73913.83766.88923.9784-5.961-50.1564-79.4444-97.2312-96.1761QC'd by Chembridge
Inhibitor1.8336117.551786Complete curve; high efficacy-5.73671.1110.9917-104.051713.5-1.10 0 0 0 0 0 0 0 0 0 0-99.203816.02712.528420.739610.99283.40560.7171-11.6101-40.2962-81.8609-95.3712-99.2038QC'd by NCGCChem
Inhibitor4.105102.203385Complete curve; high efficacy-5.38672.78680.9963-102.20330-1.10 0 0 0 0 0 0 0 0 0 0-100.6552000.44662.61961.3014-7.0848-0.1399-9.5349-70.1791-102.6138-100.6552QC'd by Microsource
Inhibitor3.177496.712985Complete curve; high efficacy-5.49791.62660.9968-95.71291-1.10 0 0 0 0 0 0 0 0 0 0-88.623100.724301.163100-0.2194-6.346-40.8346-79.8345-88.6231QC'd by Analyticon
Inhibitor6.5059128.088785Complete curve; high efficacy-5.18671.53860.9928-132.0887-4-1.10 0 0 0 0 0 0 0 0 0 0-129.49870.1476-4.8849-6.6137-8.5236-3.9326-10.9532-8.9047-15.3414-65.574-105.6081-129.4987QC'd by Axon Medchem
Inhibitor2.906193.696885Complete curve; high efficacy-5.53671.82650.9956-91.69682-1.10 0 0 0 0 0 0 0 0 0 0-89.373104.594604.2711000.8493-27.8387-73.8967-86.3827-89.3731QC'd by Cayman
Inhibitor3.2607111.298885Complete curve; high efficacy-5.48672.04790.9948-99.298812-1.10 0 0 0 0 0 0 0 0 0 0-96.590715.559213.836617.029410.599911.54637.65512.3867-12.0459-71.5767-97.3518-96.5907QC'd by NCGCChem
Inhibitor3.658592.976984Complete curve; high efficacy-5.43671.69240.9965-92.47690.5-1.10 0 0 0 0 0 0 0 0 0 0-90.6636000003.988-8.3142-20.7831-59.875-87.9355-90.6636QC'd by SigmaAldrich
Inhibitor5.798495.974484Complete curve; high efficacy-5.23672.33320.9922-96.9744-1-1.10 0 0 0 0 0 0 0 0 0 0-93.0365-0.68670.424801.8559-0.4094-1.8277-5.021-11.0122-41.926-95.6355-93.0365QC'd by SIGMA
Inhibitor4.6058102.119684Complete curve; high efficacy-5.33673.92950.9779-94.61967.5-1.10 0 0 0 0 0 0 0 0 0 0-85.5338-0.64041.64322.67266.208310.280816.117412.58977.6496-60.847-103.7496-85.5338QC'd by Sytravon
Inhibitor4.6058107.458184Complete curve; high efficacy-5.33671.47810.992-98.95818.5-1.10 0 0 0 0 0 0 0 0 0 0-93.18098.83129.08824.19858.57956.83810.28788.55-19.9304-49.1765-88.9783-93.1809QC'd by Sytravon
Inhibitor5.798498.695684Complete curve; high efficacy-5.23671.1110.9913-96.69562-1.10 0 0 0 0 0 0 0 0 0 0-90.03320.44413.12146.06443.2241-5.00040-5.7269-22.3838-41.1315-74.3311-90.0332QC'd by Selleck
Inhibitor6.5059101.664984Complete curve; high efficacy-5.18671.28760.9986-106.4121-4.7472-1.10 0 0 0 0 0 0 0 0 0 0-99.6368-3.7525-4.5439-5.9657-1.8727-5.3345-7.423-10.2197-20.0785-51.0609-82.5103-99.6368QC'd by Analyticon
Inhibitor5.035990.647784Complete curve; high efficacy-5.29793.62720.9923-92.6477-2-1.10 0 0 0 0 0 0 0 0 0 0-92.46282.39754.229-3.4667-5.4432-3.7131-3.5860.2734-4.8695-11.6501-80.2351-92.4628QC'd by Prestwick
Inhibitor5.7984107.791584Complete curve; high efficacy-5.23671.92820.99-98.79159-1.10 0 0 0 0 0 0 0 0 0 0-95.174810.4673-0.8557.541910.130413.460114.96026.5091-1.1759-44.2917-87.5379-95.1748QC'd by Chemdiv
Inhibitor4.7166102.054884Complete curve; high efficacy-5.32641.86170.9952-99.55482.5-1.10 0 0 0 0 0 0 0 0 0 0-97.60283.9695-2.5222-0.88844.87277.42362.1813-0.4619-13.1259-55.3921-92.8344-97.6028QC'd by Vitas
Inhibitor5.1678114.21784Complete curve; high efficacy-5.28671.55790.995-99.71714.5-1.10 0 0 0 0 0 0 0 0 0 0-94.569816.45520.153114.577812.385915.02249.87235.3386-3.7884-44.983-85.8105-94.5698QC'd by Chemdiv
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f19-rhfurin
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; pERTKR-AMC.
5; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two micro-liter of furin enzyme solution (40 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nano-liter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counterscreen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM pERTKR-AMC substrate in assay buffer for the Furin assay was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with AMC fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008234935 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.352 uMActivity at 0.618 uMActivity at 1.055 uMActivity at 1.924 uMActivity at 3.720 uMActivity at 5.772 uMActivity at 11.16 uMActivity at 17.32 uMActivity at 33.48 uMActivity at 50.62 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.0574123.268587Complete curve; high efficacy-5.68672.40640.9964-118.26855-1.10 0 0 0 0 0 0 0 0 0 0-115.09082.8885.40046.58594.04132.80793.37932.2835-43.9445-114.475-115.9495-115.0908QC'd by SIGMA
Inhibitor2.0574120.450687Complete curve; high efficacy-5.68672.33320.9968-118.45062-1.10 0 0 0 0 0 0 0 0 0 0-116.81524.9144-0.21651.34233.41651.011-2.1306-5.6378-45.6943-113.1005-116.7151-116.8152QC'd by Bio Vision
Inhibitor4.105101.938684Complete curve; high efficacy-5.38672.84730.9578-98.43863.5-1.10 0 0 0 0 0 0 0 0 0 0-116.35774.70634.88514.14443.42941.8409-0.45260.3312-2.0485-70.9205-76.0559-116.3577QC'd by Adooq
Inhibitor7.299892.071783Complete curve; high efficacy-5.13671.88510.982-90.07172-1.10 0 0 0 0 0 0 0 0 0 0-80.90751.9866-0.00341.8592.45192.61364.709-0.0577-7.01-25.1697-83.0089-80.9075QC'd by APAC
Inhibitor9.1899126.48883Complete curve; high efficacy-5.03674.95490.9935-123.4883-1.10 0 0 0 0 0 0 0 0 0 0-120.35874.684812.69580.55870.49710.5341.43890.9107-0.7262-3.4411-118.5135-120.3587QC'd by MedChem Express
Inhibitor7.9813140.948544Partial curve; high efficacy-5.09791.1110.9968-139.44851.5-2.10 0 0 0 0 0 0 0 0 0 0-110.67346.12721.22021.4730.7797-1.90220.5033-2.5401-12.7365-32.4047-69.1492-110.6734QC'd by Selleck
Inhibitor11.5693133.590643Partial curve; high efficacy-4.93671.34430.998-128.59065-2.10 0 0 0 0 0 0 0 0 0 0-112.79886.13264.04794.49813.35553.74434.6172.9152-3.0749-34.911-75.3804-112.7988QC'd by BOC Sciences
Inhibitor8.9552108.061143Partial curve; high efficacy-5.04792.72020.9893-109.0611-1-2.10 0 0 0 0 0 0 0 0 0 0-113.6053-2.5498-0.0161-0.90541.549-1.6624-1.035-0.2871-3.0955-5.3823-47.9419-113.6053QC'd by Prestwick
Inhibitor14.5649127.955942Partial curve; high efficacy-4.83671.24750.9826-128.4559-0.5-2.10 0 0 0 0 0 0 0 0 0 0-105.98672.2922-1.30330.06040.33271.0331.7306-15.2556-2.8882-32.157-68.6091-105.9867QC'd by Microsource
Inhibitor14.949298.195442Partial curve; high efficacy-4.82541.210.9903-97.69540.5-2.10 0 0 0 0 0 0 0 0 0 0-86.60942.67262.2733-2.4477-0.1168-0.6014-1.3047-4.1854-5.4249-37.0086-59.94-86.6094QC'd by Analyticon
Inhibitor16.3421115.928742Partial curve; high efficacy-4.78671.41630.997-118.4287-2.5-2.10 0 0 0 0 0 0 0 0 0 0-99.18650.721-0.0234-3.3938-3.533-1.967-3.116-5.2659-9.9377-23.4562-59.675-99.1865QC'd by SIGMA
Inhibitor23.083990.567541Partial curve; high efficacy-4.63674.0950.9634-90.56750-2.10 0 0 0 0 0 0 0 0 0 0-83.39554.74497.57771.47721.30211.6670.6907-1.2401-5.9881-10.181-16.7566-83.3955QC'd by Specs
Inhibitor23.083975.77441Partial curve; partial efficacy-4.63674.0950.992-75.2740.5-2.20 0 0 0 0 0 0 0 0 0 0-69.52570.34681.32922.0132.5351.636-1.8741-0.19931.5465-2.9321-17.123-69.5257QC'd by MedChem Express
Inhibitor16.342192.057741Partial curve; high efficacy-4.78671.69240.9944-95.1547-3.097-2.10 0 0 0 0 0 0 0 0 0 0-84.8081-1.7048-2.7043-2.7328-3.1309-0.9142-2.2389-6.802-4.7221-18.0355-46.4212-84.8081QC'd by NCGCChem
Inhibitor25.900568.518740Partial curve; partial efficacy-4.58674.0950.9879-72.9929-4.4742-2.20 0 0 0 0 0 0 0 0 0 0-67.4188-3.157-0.3952-2.6752-3.6727-6.2029-4.4808-5.843-6.458-7.6543-12.7605-67.4188QC'd by Sequoia
Inhibitor18.336242.376921Partial curve; partial efficacy-4.73671.41630.9611-43.3769-1-2.20 0 0 0 0 0 0 0 0 0 0-38.05-3.369-1.8439-1.25460.0268-0.6973-0.09930.30380.0057-12.0993-17.8476-38.05QC'd by Microsource
Inhibitor20.573554.32321Partial curve; partial efficacy-4.68672.25260.9506-54.823-0.5-2.20 0 0 0 0 0 0 0 0 0 0-53.7485.10192.19790.06740.0829-1.10770.4012-3.1391-4.7207-8.4582-17.4267-53.748QC'd by Sytravon
Inhibitor18.336246.34721Partial curve; partial efficacy-4.73671.62590.9854-44.3472-2.20 0 0 0 0 0 0 0 0 0 0-38.90092.97871.94912.18482.73582.0412.25672.6921-0.4112-6.8174-16.7494-38.9009QC'd by Analyticon
Inhibitor14.564950.099621Partial curve; partial efficacy-4.83671.210.992-51.0996-1-2.20 0 0 0 0 0 0 0 0 0 0-41.74210.7762-0.4111-2.9919-2.3469-1.15660.2368-2.4226-3.9572-14.3837-27.3644-41.7421QC'd by Analyticon
Inhibitor20.573541.122920Partial curve; partial efficacy-4.68672.33320.9549-41.12290-2.20 0 0 0 0 0 0 0 0 0 0-40.31660.94294.30531.2929-3.02070.36030.3042-0.5695-2.7371-4.0541-12.0009-40.3166QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL985757
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0%
Inhibition=9.1%
Inhibition=0%
Inhibition=0%
Inhibition=0%
Inhibition=0%
Inhibition=0%
Inhibition=0%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL986615
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL986614
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=70%
Activity=60%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
Activity=70%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL986617
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL1176153
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2010
Volume: 73
Issue: 7
First Page: 1193
Last Page: 1195
DOI: 10.1021/np1000945

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
deltaA=0.14
deltaA=0.29
deltaA=0.48
deltaA=0.56
deltaA=0.75
deltaA=0.68
deltaA=0.13
deltaA=0.24
deltaA=0.23
deltaA=0.17
deltaA=0.3
deltaA=0.24
deltaA=0.69
deltaA=0.51
deltaA=0.72
deltaA=0.66
deltaA=0.29
deltaA=1.18
deltaA=0.47
deltaA=0.18
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Raji
External ID: CHEMBL986616
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s

Target ChEMBL ID: CHEMBL614628
ChEMBL Target Name: Raji
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
Activity>80%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL986611
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=60%
Inhibition=82.7%
Inhibition=62.6%
Inhibition=76.6%
Inhibition=71.6%
Inhibition=74.1%
Inhibition=69.6%
Inhibition=70.1%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40657
Protocol: Tox21 Assay Protocol Summary:

300 DT40 mutant cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00617 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.535 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.01123.097-15.61374.831817.24522.68492.87025.838-1.15092.4566-15.0143-1.83128.71463.75322.72683.0112QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.1785-10.892-15.6985-0.69210.4103-15.63332.8403-15.8637-6.5703-13.149-26.3626.1142-10.7498-15.5641-24.2196-2.1785QC'd by Sigma DiscoveryCPRCytotoxic68.589691.523642Partial curve; high efficacy-4.16373.24750.8975-95.1787
Inactive04-10.4836-24.2062-15.4625-22.1853-17.0029-23.7071-26.4511-5.4538-39.9631-45.6107-35.4677-32.0907-29.217-24.9641-27.9971-10.4836QC'd by Sigma DiscoveryCPRCytotoxic61.130629.401520Partial curve; partial efficacy; poor fit-4.21371.88510.8107-31.9015
Inactive04-4.59729.3751-8.1926-3.89550.6461-8.566213.4774-0.62345.5343-3.2761-6.0086-5.24710.8659-3.3104-0.8139-4.5972QC'd by Sigma DiscoveryCPRInactive04.95490.6911-27.7726
Inactive01.3310.4841-18.2848-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4341-15.6941-0.6359-0.217-0.01279.76010.47981.0579-3.8901-4.4074-0.2904-14.3809-1.6368-26.0707-15.5655-15.4341QC'd by Sigma DiscoveryCPRCytotoxic68.589696.936120Single point of activity-4.16374.95490.9116-96.8607
Cytotoxic68.589648.251420Single point of activity-4.16374.50450.669-42.75145.5-30 0 0 0 0 0 0 0 0 0 0 1 0 0 0-32.76366.68717.171221.5873-4.0029-2.3442-2.24135.53994.60832.4453-0.50548.148-24.60336.40680.6319-32.7636QC'd by Sigma DiscoveryCPRCytotoxic68.589648.174420Single point of activity-4.16374.95490.9289-45.8879
Inactive00.30.7121-33.8051140 0 0 0 0 0 0 0 0 0 0 1 0 0 0-24.382310.43845.12726.81657.22591.8658-8.6709-16.2528-6.24420.3161-1.6373-7.5312-91.6148-26.0875-17.5667-24.3823QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic30.637967.376140Partial curve; high efficacy-4.51370.90.775-65.03912.337-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-60.304212.047412.9559-2.1973-12.63497.3969-3.88253.660712.6478-6.4422-9.9361-12.776-9.7544-22.4301-24.4994-60.3042QC'd by Sigma DiscoveryCPRCytotoxic61.130636.052220Partial curve; partial efficacy; poor fit-4.21374.95490.8632-33.5522
Cytotoxic61.1306111.553142Partial curve; high efficacy-4.21373.990.9734-113.6335-2.0804-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.65118.3666-2.0713-3.7808-2.35050.04213.1312-0.1348-6.3457-2.025-7.1259-0.3043-6.8314-6.1688-21.3977-95.6511QC'd by Sigma DiscoveryCPRInactive0
Inactive04-12.7888-1.057-2.0848-0.7554-6.8445-0.3896-2.5669-0.3877-3.83473.37538.0661-13.2548-2.828516.492-3.484-12.7888QC'd by Sigma DiscoveryCPRInactive01.69240.56086
Cytotoxic68.5896120.709842Partial curve; high efficacy-4.16374.95490.9332-122.3541-1.6443-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.4749-0.52770.547410.1427-1.25254.012-10.9614-1.4029-7.26650.8155-18.27654.3116-4.27371.9509-11.5455-99.4749QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6075-28.619-440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.4325-14.8758-0.7818-11.7063-0.11123.04971.97010.8638-15.4171-14.52550.3742.40541.2793-11.955-27.2415-28.4325QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6053-25.3863340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.9053-3.0798-0.16165.81434.36872.6264-2.68023.478213.64463.777-0.6631-2.940811.09824.56250.5366-19.9053QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.2887-9.33222.806-1.96982.835-19.1802-2.244-2.376111.6639-4.3953-0.88963.7875-1.1556-17.5934-15.146-2.2887QC'd by Sigma DiscoveryCPRInactive04.95490.74112
Cytotoxic68.5896121.561120Single point of activity-4.16374.95490.9451-122.6489-1.0878-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-100.2033-11.91628.5759-4.0103-8.04752.09744.9269-4.8191-8.6034.1695-6.8431-3.09872.96934.092-4.7679-100.2033QC'd by Sigma DiscoveryCPRInactive0
Inactive00.60.4241-16.80689.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.33918.7614-0.1122-2.521314.32534.912525.50638.89340.001311.5099-6.67791.0565-0.13852.7506-11.651-12.339QC'd by SIGMACytotoxic20Single point of activity
Inactive00.50.4566-0.24781040 0 0 0 0 0 0 0 0 0 0 0 0 0 02.05936.68268.657811.23617.42261.45222.14479.27011.79030.5244-3.08084.58743.84151.4091-6.45652.0593QC'd by Sigma DiscoveryCPRInactive04.0450.6801-25.4596
Inactive04.95490.4416-12.802440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.75170.2533-2.853315.69095.351413.8457-0.7219-3.2206-0.93875.440912.5372-1.28440.86326.1393-10.3064-12.7517QC'd by Sigma DiscoveryCPRInactive0
Inactive01.64360.3324-17.01442.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.845410.67053.9496.78270.3479-1.2699-8.220512.82270.96571.1019-3.13092.35830.7293-0.3373-3.38-10.8454QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic0.136975.828189Complete curve; high efficacy-6.86371.46410.9678-76.2529-0.4248-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.61070.6376-4.1922-1.0881-0.5964-10.0644-14.6504-42.7191-72.2882-55.2459-69.9677-74.6041-73.5035-77.875-80.4615-83.6107QC'd by Sigma DiscoveryCPRCytotoxic0.216966.648687Complete curve; high efficacy-6.66374.95490.9621-68.4642
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL985758
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=19.1%
Inhibition=34.3%
Inhibition=20.5%
Inhibition=40.6%
Inhibition=33.6%
Inhibition=39.5%
Inhibition=30.5%
Inhibition=31.9%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL986613
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s
Standard TypeStandard RelationStandard ValueStandard Units
IC50=220molar ratio
IC50=400molar ratio
IC50=270molar ratio
IC50=398molar ratio
IC50=320molar ratio
IC50=340molar ratio
IC50=310molar ratio
IC50=315molar ratio
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40653
Protocol: Tox21 Assay Protocol Summary:

300 DT40 wild type cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00616 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.521 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Cytotoxic26.603236.966420Partial curve; partial efficacy-4.57512.72020.8066-39.4664-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.472-0.25570.1894-1.0942-0.5827-4.2967-5.868-6.7254-11.93875.14311.8075-4.2794-0.4027-4.0199-15.1045-32.472QC'd by BIOMOLCytotoxic29.849326.509520Partial curve; partial efficacy; poor fit-4.52512.63840.9875-26.5095
Inactive01.86170.797812.5-1.95440 0 0 0 0 0 0 0 0 0 0 0 0 0 013.436-3.4844-0.2195-0.0323-3.9215-4.0814-0.0401-0.8641-1.671-6.21177.13323.394912.058516.39137.133513.436QC'd by LabotestInactive0
Cytotoxic33.491572.589320Single point of activity-4.47514.95490.87-70.09812.4912-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.7558-5.4321-0.79632.7012-4.9918-9.0E-40.18971.83576.58097.28190.48664.686-3.50518.42064.2376-61.7558QC'd by NIEHSCytotoxic33.491548.466820Single point of activity-4.47514.95490.915-47.5343
Cytotoxic33.491562.335220Single point of activity-4.47514.95490.9666-60.31812.0171-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.91061.26516.74810.56595.4752-0.56413.2722-2.04112.0693-0.9569-1.23341.81252.32623.2022-1.746-52.9106QC'd by SigmaAldrichCytotoxic33.491555.158120Single point of activity-4.47514.95490.9353-53.8129
Cytotoxic0.059689.024292Complete curve; high efficacy-7.22511.78850.992-89.7743-0.75-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.2674-0.2675-0.0127-3.3186-0.3113-8.6624-24.8555-49.0768-77.442-90.0161-91.8738-92.0934-92.3604-91.6897-87.2484-79.2674QC'd by SigmaAldrichCytotoxic0.094489.564392Complete curve; high efficacy-7.02511.86170.9962-91.4613
Cytotoxic6.682427.545720Partial curve; partial efficacy; poor fit-5.17512.25260.861-25.54572-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.28819.49086.5142-4.21044.75951.44771.72043.2832-0.4826-3.55211.5616-1.0976-1.442-21.2425-19.2902-26.2881QC'd by BIOMOLInactive03.24750.9525-18.8964
Cytotoxic23.710193.126841Partial curve; high efficacy-4.62513.92950.9489-91.0412.0858-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.2443-3.1984-0.199713.89730.60014.4648-8.30652.45650.811-0.2967-0.07760.088610.98955.4259-31.5062-85.2443QC'd by BIOMOLCytotoxic29.8493108.411840Partial curve; high efficacy-4.52514.0950.9921-108.5943
Inactive02.24810.5195-8.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5751-5.85510.12813.73894.13328.24181.27954.25414.65918.42590.13073.147412.08273.9666.749912.5751QC'd by ART-CHEMInactive02.25260.48479.5
Cytotoxic9.439234.203321Complete curve; partial efficacy-5.02513.1320.894-32.31981.8834-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.61375.31591.7117-0.85858.78-0.0810.7177-0.76264.06551.1951-4.8016-3.6366-0.459-14.2043-30.7093-31.6137QC'd by MicrosourceCytotoxic26.603248.471820Partial curve; partial efficacy-4.57512.53340.9934-48.0851
Inactive04-16.177-0.1697-9.1792-4.21641.9066-5.3806-0.96160.4121-5.1331-3.3638-0.05870.4161-5.1357-5.4857-1.2925-16.177QC'd by TocrisInactive04.44950.918310
Cytotoxic10.590985.872682Complete curve; high efficacy-4.97513.92950.9788-84.34711.5254-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.19184.19197.6194-2.25542.112711.554-1.9447-0.363-1.4443-5.1393-0.2045-0.4497-1.9204-25.8199-80.5151-83.1918QC'd by BIOMOLCytotoxic18.8336109.803841Partial curve; high efficacy-4.72512.33320.9775-108.1925
Inactive0410.93317.2308-0.76461.9030.8854-12.36610.0538-0.03730.03780.85910.1617-0.68821.54178.41924.24810.9331QC'd by DPISMRInactive02.40640.437310
Inactive03.92950.545916.5-1.032140 0 0 0 0 0 0 0 0 0 0 0 0 0 015.0573-1.0016-2.8234-2.88181.553-4.404-7.94341.5739-2.1443-4.82762.255.35516.2847-6.12956.377615.0573QC'd by TimtecInactive00.70.44975.5
Cytotoxic29.8493110.252640Partial curve; high efficacy-4.52512.30310.9779-109.67690.5757-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.08850.20916.1543-0.0464-5.63920.8022-1.55-1.65864.52973.84694.02740.9875-0.3079-12.105-32.034-83.0885QC'd by SigmaAldrichCytotoxic23.7101107.138841Partial curve; high efficacy-4.62513.1320.9922-106.8899
Cytotoxic4.216370.168183Complete curve; high efficacy-5.37511.82650.9542-75.4788-5.3107-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.79042.2008-11.44290.78810.9581-3.3197-4.8289-11.2303-7.4383-13.5817-10.6197-19.4834-33.1317-70.7599-75.9063-66.7904QC'd by SigmaAldrichCytotoxic6.682485.17583Complete curve; high efficacy-5.17512.25260.9899-85.1455
Inactive040.61421.36820.7153-0.4571-0.0959-0.8039-4.1432-4.6019-4.3611-0.5841.49151.5429-6.74321.21242.11860.6142QC'd by Toronto ResearchInactive0
Inactive02.24810.6569-25.4435040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-6.9489-9.0935-1.1970.4962-0.2828-0.2884-0.6514-0.4859-0.9558-0.834612.2159-0.8399-4.0992-10.64-20.7863-6.9489QC'd by MicrosourceInactive03.990.9151-12.2781
Cytotoxic11.883290.050282Complete curve; high efficacy-4.92512.47290.973-88.31971.7305-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.10032.5615-9.7822-0.0524-0.0447.70862.0062.3996-2.72396.63640.75558.2888-9.0916-27.0183-69.093-87.1003QC'd by SigmaAldrichCytotoxic16.7855111.787642Partial curve; high efficacy-4.77512.25260.9888-110.5514
Inactive045.64962.63765.96770.68332.59292.6537-0.6376-1.73942.60582.96495.1854-1.38641.1535-2.51674.08825.6496QC'd by MicrosourceInactive0
Cytotoxic0.013384.417393Complete curve; high efficacy-7.87513.06540.9777-79.41735-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-65.1036-0.246612.5138-0.0588-0.1182-44.5452-81.5515-76.6214-76.487-79.8263-80.1839-83.5104-84.3071-81.9727-77.6097-65.1036QC'd by SigmaAldrichCytotoxic0.018881.862693Complete curve; high efficacy-7.72513.1320.9924-80.8961
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL986612
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2003
Volume: 66
Issue: 2
First Page: 200
Last Page: 205
DOI: 10.1021/np020290s
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=89.2%
Inhibition=100%
Inhibition=90.4%
Inhibition=97.5%
Inhibition=95.8%
Inhibition=96.8%
Inhibition=93.1%
Inhibition=94.2%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ARN311
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD, the plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001156673 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-0.31012.60345.2328-7.4588-22.40130.375-0.1984-2.3931-1.2564-8.09639.3404-3.06595.9663-1.58734.5199-0.3101104-3.9642
Inactive04.95490.3643-22.3778-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.78168.0187-3.6037-16.9815-3.8818-2.29095.01652.79550.20882.48671.7989-1.54061.7447-0.235-0.7352-16.7816104-2.2059
Inactive043.57430.8747-3.9166-24.45945.89297.288-1.3695-3.01450.7455-3.3797-5.98945.1771-6.5534-24.68652.32073.57431047.5783
Inhibitor4.900828.1010Complete curve; partial efficacy-5.35974.95490.9394-35.05232.1161-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.73956.47820.5836-2.50425.18514.7563-0.0076-2.0536-0.46464.28292.77760.8265-36.8316-41.2003-30.0841-28.73950Complete curve; partial efficacy-5.30974.95490.9573-29.601-1.5-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.6016
Inactive04.95490.4916-1.809223.566940 0 0 0 0 0 0 0 0 0 0 0 0 0 115.21822.11765.5545-21.01622.15544.6396-7.65691.92745.3607-1.5953-4.5468-0.6799-3.76644.0052-3.946215.2181044.8462
Inactive01.10.6588302.061440 0 0 0 0 0 0 0 0 0 0 0 0 0 025.1973-3.28439.6853-7.44880.23246.60482.10544.31735.821-1.74083.4799.49854.81177.719714.363925.1973103.990.399610.5-1.1740 0 0 0 0 0 0 0 0 0 0 0 0 0 09.5095
Inactive049.77122.536-6.562-5.3417-5.9234-39.9488-5.968110.84588.9255-0.24792.9806-6.8833-4.3579-1.6090.52489.7712104.95490.5937-14.8893140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4453
Inactive04.95490.4788-6.55483.540 0 0 0 0 0 0 0 0 0 0 0 0 0 14.7498-1.96698.88083.7797-1.19723.771-1.813610.85376.00320.95625.55565.91760.0775-8.7957-4.39424.7498104.95490.4162-8.4461040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.3101
Inactive04-0.6526-2.05915.3448-1.516310.020411.48099.60240.498-2.8963-39.9716-6.1745-8.80585.1369-5.28877.5723-0.6526104-6.969
Inactive04.95490.66612.5-2.425140 0 0 0 0 0 0 0 0 0 0 0 0 0 12.24016.20333.29734.4221-3.8862-9.9376-8.1449-6.8511-1.9679-2.63936.38114.984911.18028.177315.06922.24011041.9909
Cytotoxic38.68696.04760Complete curve; high efficacy; poor fit-5.16240.90.9679-177.45466.148-1.30 0 0 0 0 0 0 0 0 0 1 0 0 0 0-159.8693.34737.22885.9146-7.062810.2393-3.541.646215.78721.384-48.661194.1427-91.3502-99.691-149.1613-159.8690Complete curve; high efficacy; poor fit-5.96242.72020.9288-80.8591.6099-1.30 0 0 0 0 0 0 0 0 0 1 0 0 0 1-28.5303
Inactive04.44950.3508-1.0294640 0 0 0 1 0 0 0 0 0 0 0 0 0 19.47328.76138.5543-0.62945.1568-40.71868.076-9.6078-4.29426.8911-0.0474-2.5230.1723.3311-4.05699.47321040.4281
Inactive04-2.2793-16.1966-0.33634.1517210.08650.3009-24.2384.08051.40143.5487-26.7861-1.9657-20.1052-24.4126-2.7694-2.2793104.95490.479-5.1746-140 0 0 1 0 0 0 0 0 0 0 0 0 0 1-2.7494
Inconclusive0Complete curve; partial efficacy; poor fit-4.71813.57220.8573-36.7503-1.463-1.40 0 0 0 1 0 0 0 0 0 0 0 0 0 0-36.42773.30930.74498.2023-4.0947-36.5254-9.3605-10.5624-1.31474.1105-3.7252-2.4539-2.446-11.8667-32.5393-36.4277102.72020.3396-13.3921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.4638
Inconclusive040.358-5.80154.891-0.6919-11.0079-19.6144-7.4623-14.0156-21.4722-10.8579-10.9036-26.1342.925-6.5462-3.80530.35805-38.8248
Inactive04-0.5281-8.24323.7508-2.013114.742614.78921.06921.9847-2.24831.13697.4486-0.4716-7.2648-0.5094-1.7998-0.5281104-2.7813
Inactive0413.8550.0073-4.1723-6.3962.5792-2.82416.1567-21.5019-29.61284.9675-2.8564-1.19920.5899-22.10866.170313.855104.95490.46645-2.923640 0 0 0 0 0 0 0 0 0 0 0 0 0 09.0459
Inactive0410.291510.321.9833-3.4895-1.877-21.07441.25514.61272.0503-1.5541-16.7527-14.5002-14.25263.41944.086110.2915104.95490.33674-3.212740 0 0 0 0 0 0 0 0 0 0 0 0 0 03.6514
Inactive0410.5698-4.85215.51528.02770.6693-0.41221.17524.28157.796711.6703-2.4145-3.5827-17.7432-1.69017.194110.56981040.1918
Inconclusive0Single point of activity-4.22274.95490.346146.34681.113330 0 0 0 0 0 0 0 0 0 0 0 0 0 036.2338.384418.3726-16.520613.7807-9.255918.1763-8.395215.30761.533-21.84513.56131.7241-8.64971.984936.23310413.1112
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ARV616
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD, the plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux (PerkinElmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive03.990.489514.50.387740 0 0 0 0 0 0 0 0 0 0 0 0 0 013.2432-1.4837-1.6377-3.01028.48310.8069-0.8928-2.96526.0294-1.26660.4119-2.01115.2633-2.51414.891813.2432QC'd by NCIInactive0
Cytotoxic13.448167.03541Partial curve; partial efficacy-4.87132.40640.9483-65.88481.1503-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.76121.68940-2.57354.3167-3.07571.9178-6.31482.56240.402502.28668.7363-6.0795-46.5284-59.7612QC'd by NCICytotoxic13.448169.062181Complete curve; high efficacy-4.87132.33320.9121-70.6029
Inactive043.7161-12.2751-2.3002-1.6316-15.18541.85713.3342-2.9699-2.0413-13.1818-11.27081.9534-1.39975.1131.14923.7161QC'd by NCIInactive0
Cytotoxic26.832590.849140Partial curve; high efficacy-4.57134.95490.8098-100.2645-9.4153-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.95134.2098-19.4478-12.20980.47056.202-13.0275-8.0765-22.0722-18.7099-9.553-20.4345-22.753-16.0947-14.5884-87.9513QC'd by SigmaAldrichCytotoxic26.8325110.606120Single point of activity-4.57134.95490.9757-108.5139
Cytotoxic6.00741.257822Complete curve; partial efficacy-5.22134.95490.9195-42.3449-1.0871-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.8534-4.4571-8.2748-4.9404-4.3576-4.27765.7531-3.633-1.35980.4958-0.35669.6775-1.5757-32.4825-46.1934-38.8534QC'd by NCICytotoxic10.682254.444561Complete curve; partial efficacy-4.97131.96730.9226-56.5233
Inconclusive26.8325150.171210Single point of activity-4.57134.95490.961153.07962.908430 0 0 0 0 0 0 0 0 0 0 0 0 0 0134.99081.82296.173310.52991.98726.71850.93511.7089-2.14774.2188-0.774613.82718.41320.8303-0.7732134.9908QC'd by NCIInactive0
Inactive01.22210.41864.5-1.930740 0 0 0 0 0 0 0 0 0 0 0 0 0 04.5856-1.3196-3.69221.36491.0832-0.47954.06122.32967.17138.75533.06883.76594.0884-2.7456.66394.5856QC'd by NCIInactive0
Inconclusive7.562471.092210Partial curve; partial efficacy-5.12130.50.76765.1454-5.94682.20 0 0 0 0 0 0 0 0 0 0 0 0 0 046.6342-12.7974-15.4917-0.52960.2388-0.06146.16276.93520.91150.8063.362617.856616.391350.940121.053146.6342QC'd by NCIInactive00.90.42887.5
Inactive041.29870.26417.9226-0.14278.425418.07622.74773.60225.78683.0364-1.92855.85980.202813.7133.40951.2987QC'd by NCIInactive04.95490.4355-1.0732
Inactive04.95490.7188-15.88482.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.18360.6525-7.001912.4053-1.472514.74161.3425-4.94940.5613-16.3729-15.2237-21.154-15.1498-14.4462-14.3984-13.1836QC'd by LabotestInactive04.0950.5528-3.855
Inactive04-20.3003-1.0649-10.444-8.75741.6777-10.2125-0.2685-12.5512-13.1255-0.925-7.2786-11.9660.72411.86010.3951-20.3003QC'd by NCIInactive04.95490.5261-23.8123
Inactive04.95490.39593-2.823940 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5673-4.4366-1.0393-2.2619-0.07424.96018.6841.9313-1.37982.68612.98159.12642.3321-1.23280.89963.5673QC'd by NCIInactive04.95490.3659-17.5729
Inactive03.51170.37556-6.443540 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5687-11.2029-0.0395-5.077916.227812.909711.73155.59741.1191-0.30784.957313.204-1.0463-0.93975.026.5687QC'd by NCIInactive0
Cytotoxic16.930159.884821Partial curve; partial efficacy-4.77133.06540.9188-51.38618.4987-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.574-0.8676-0.623810.27414.57089.75410.356513.39938.374912.692113.1394.955512.28047.6603-22.9522-46.574QC'd by NCICytotoxic21.313867.884841Partial curve; partial efficacy-4.67131.71370.9408-70.3536
Inactive046.959-0.79660.388-1.0081-2.52160.3745-0.9254-0.49080.00549.84677.2309-1.9095-1.85539.9124-2.0026.959QC'd by NCIInactive04.95490.419911
Inactive042.67970.81320.67155.9018-12.1997-1.08692.54263.33172.1845-1.5877-1.7464-0.16223.45931.06253.25792.6797QC'd by NCIInactive00.90.582-33.3132
Inactive040.6948-5.0672-1.3719-2.8148-0.91130.70280.4556-2.1179-0.7521-3.09620.8353-4.0848-8.6081-7.87880.02230.6948QC'd by NCIInactive0
Inactive042.34697.3341-10.0256-1.419223.5642-8.5631-10.8052-3.591-20.1453-0.5542-4.3357-14.70621.0266-1.0905-3.56012.3469QC'd by ChembridgeInactive01.28760.3307-0.9589
Inactive04-3.4301-3.1069-2.9432-2.5794-6.3741-1.8324-1.6472.01951.609-1.9177-3.2478-5.222-6.2901.2803-3.4301QC'd by NCIInactive0
Inactive04.95490.3885-13.31410.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.5118-2.3747-1.76850.3253-8.23524.83090.23524.69012.66612.5173-5.7374.83960.06945.051-0.7597-11.5118QC'd by NCIInactive04.95490.7687-23.7162
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ARA345
Protocol: Tox21 Assay Protocol Summary:

AR-bla cells were dispensed at 2,000 cells/6 uL/well of assay medium into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37C and 5% CO2 for 16 h. Then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000513298 uM-Replicate_1W460-Activity at 0.0001155496 uM-Replicate_1W460-Activity at 0.0002337114 uM-Replicate_1W460-Activity at 0.0005013406 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.19 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.14 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive042.6547-0.7130.5183-2.1304-1.9979-1.3265-0.01867.93330.6342-0.1739-0.62145.78417.3104-0.178-7.78592.6547104-3.7851
Inactive042.32568.2060.78711.46461.73150.42748.95695.63553.13353.05-0.77786.510113.61665.19684.14212.3256104-12.1995
Activator18.995930.02560Partial curve; partial efficacy-4.62132.78680.92154.46541.7612.20 0 0 0 0 0 0 0 0 0 0 0 0 0 043.4865-0.3029-0.49880.781111.26170.50915.70490.5268-1.4541-1.24463.5091-0.04480.11754.60116.157343.48650Partial curve; partial efficacy; poor fit-4.72133.19250.842124.5-5.52562.40 0 0 0 0 0 0 0 0 0 0 0 0 0 021.4158
Inactive04-0.0347-9.9873-2.6594-3.1088-0.3377-4.6023-3.692-4.8732-3.2091-0.3806-2.9603-2.7049-2.0287-2.7078-4.4199-0.034710419.5826
Inactive04-3.0982-0.68985.32923.8884-0.5236-0.6926-0.0665-0.01790.06230.6225-0.01212.8929-0.0136.26380.0671-3.0982104-0.058
Activator0.095246.28080Single point of activity-7.07134.95490.994638.71930.012430 0 0 0 0 0 0 0 1 1 1 1 1 1 1-7.8911.05910.73320.2659-1.2397-0.34750.40284.953335.975324.95868.10683.1498-1.567-1.4611-9.018-7.8910Complete curve; partial efficacy-7.02134.95490.935156.861410.58061.20 0 0 0 0 0 0 0 0 1 1 1 1 1 11.9859
Activator23.914570.16480Partial curve; partial efficacy; poor fit-4.62132.72020.943457.80860.94592.40 0 0 0 1 0 0 0 0 0 0 0 0 0 045.6562-1.0317-0.1745.39450.219443.7222-1.1805-5.8784-0.02260.5515.28252.84113.27656.642615.775845.65620Partial curve; high efficacy-4.62134.0950.810970.22490.06012.10 0 0 0 0 0 0 0 0 0 0 0 0 0 061.6926
Inactive04-0.6673-1.46352.2059-0.10010.6518-1.9790.24740.0709-3.6651-2.02110.50780.1094-1.5942-0.2166-1.4096-0.6673101.46410.3579-1-5.240440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.2755
Inactive04.95490.918711-0.437940 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8709-0.28480.04410.1474-0.1889-0.8305-2.44820.3683-0.4505-0.03670.1234-0.0247-0.2328-0.6585-0.49048.8709100.90.32894-5.857240 0 0 0 0 0 0 0 0 0 0 0 0 0 03.3152
Inactive041.43112.49333.1415-1.4347-0.6951-2.9577-0.15485.14650.1923-0.9057-0.04053.13677.31274.4602-6.46961.4311104-10.1923
Inconclusive04.44950.831416.50.329840 0 0 0 0 0 0 0 0 0 0 0 0 0 015.1543.023-0.00470.0318-0.8095-2.6418-0.00733.1252-0.6141-2.2083-0.12241.3932.2333-2.27025.32415.1540Partial curve; partial efficacy; poor fit-4.62134.0950.71920.5-0.60832.40 0 0 0 0 0 0 0 0 0 0 0 0 0 017.7834
Activator26.832536.12090Partial curve; partial efficacy; poor fit-4.67131.10.844321.49582.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.97210.59651.95030.5658-0.48080.4727-1.67022.251.19386.2013.92882.9774.918811.35138.676724.97210Single point of activity-4.57134.95490.895234-2.120930 0 0 0 0 0 0 0 0 0 0 0 0 0 030.3051
Inactive01.46410.624412.51.463440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4167-0.55140.01974.80125.9584-0.8638-0.0453-0.07061.48992.3896-0.76474.52240.82814.64997.782210.41671048.965
Inactive04.95490.597170.740440 0 0 0 0 0 0 0 0 0 0 0 0 0 06.07977.7111-0.0960.17431.623-3.96631.7402-0.65390.2819-0.27796.62437.06165.35719.67176.21496.07971042.9632
Inactive040.05040.05030.33210.3741-0.88310.70860.743713.5848-2.956-0.040.6316-0.27470.2085-0.9317-5.02210.0504103.51170.697212-1.376840 0 0 0 0 0 0 0 0 0 0 0 0 0 09.6003
Inactive04.95490.5151-12.03081.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.8591.10191.43572.73238.02021.79190.0334-4.95640.1170.62880.06953.5324-0.1651-0.10014.8039-10.859103.92950.4602-13.0918040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.7432
Inactive04.95490.3517-1.127240 0 0 0 0 0 0 0 0 0 0 0 0 0 13.82333.9732-2.00965.51243.0247-0.01220.55981.88060.4643.8758-0.28-2.6058-2.04710.0558-0.01653.8233104-1.1763
Inconclusive15.08923.504-0.08610.50272.7158-3.1697-2.8957-0.2353-0.01494.66570.18430.35262.0111-2.86430.2611.87883.9696-0.08610Partial curve; partial efficacy; poor fit-4.87131.66040.9538-22.7891-1.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.6576
Inconclusive04.95490.7209-2.7152140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.09050.36180.74711.1205-0.38111.42562.0678-0.18930.08741.98230.175-2.9381-3.5127-3.2857-0.61470.09050Partial curve; partial efficacy; poor fit-4.57134.95490.855226-4.23722.40 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8381
Inactive04-0.630.1249-0.77332.204815.13662.89312.38250.15032.077917.27650.08482.06247.5723-0.4211.8017-0.63104-11.6985
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:AR protein [Homo sapiens]
External ID: MDAN535
Protocol: Please refer to other AIDs 743042 and 743041 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AR antagonist mode assay (AID 743042) and cell viability counter screen (AID 743041). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryAR ActivityAR Potency (uM)AR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonistinactive0NCI
inconclusive antagonist (cytotoxic)active antagonist18.12455735-111.5015527active antagonist20.3992366-95.33077837NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist33.49145963-71.97733202active antagonist33.49145963-45.59717193SigmaAldrich
inconclusive antagonist (cytotoxic)active antagonist24.63773286-89.63619394inconclusive antagonist33.49145963-42.65251674NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist30.2961402-37.60775273NCI
inactiveinactive0inconclusive antagonistLabotest
active antagonistactive antagonist28.72548756-74.97879422inconclusive antagonist32.33061121-27.15821987NCI
active antagonistactive antagonist27.64399095-64.36631028inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-64.79576401active antagonist32.7130197-37.67340069NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
inconclusive agonistinconclusive agonistinactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Bile salt export pump
External ID: CHEMBL4017550
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Drug Metab Dispos
Year: 2012
Volume: 40
Issue: 12
First Page: 2332
Last Page: 2341
DOI: 10.1124/dmd.112.047068

Target ChEMBL ID: CHEMBL6020
ChEMBL Target Name: Bile salt export pump
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
49.32IC50=49320nM
1000IC50>1000000nMOutside typical range
46.82IC50=46820nM
144.7IC50=144700nMOutside typical range
733.5IC50>733500nMOutside typical range
6.9IC50=6900nM
10IC50<10000nM
37.4IC50=37400nM
1000IC50>1000000nMOutside typical range
919.1IC50>919100nMOutside typical range
343.7IC50=343700nMOutside typical range
833.1IC50=833100nMOutside typical range
1000IC50>1000000nMOutside typical range
10IC50<10000nM
276.2IC50=276200nMOutside typical range
1000IC50>1000000nMOutside typical range
1000IC50>1000000nMOutside typical range
1000IC50>1000000nMOutside typical range
1000IC50>1000000nMOutside typical range
649.1IC50=649100nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: MDAV150
Protocol: Tox21 Assay Protocol Summary:

MDA-kb2 AR-luc cells were dispensed at 3,000 cells/4 uL/well of culture medium into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 0% CO2 for 5 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 0% CO2 for 16 h. After 15.5 h incubation, 1uL of CellTiter-Fluor reagent (Promega) was added using a Bioraptr FRD to each plate for measuring cytotoxicity. The fluorescence intensity was quantified on a ViewLux plate reader (PerkinElmer, Shelton, CT) following 30 min incubation at 37C and 0% CO2.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002746821 uM-Replicate_1Activity at 0.0005960927 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.16 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.95 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.9341-4.0025-4.45586.8198-1.1644-4.92122.01380.18830.932-6.078-2.34493.01673.4002-5.54413.9341QC'd by NCIInactive04.50450.56978
Cytotoxic15.6421110.147982Complete curve; high efficacy-4.80572.72020.9603-107.6072.5408-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0-95.90644.73640.534-1.15171.49885.7269-3.13844.6023-2.5915.101-0.7039-0.1448-2.8091-85.7578-95.9064QC'd by NCICytotoxic26.603280.513740Partial curve; high efficacy-4.57513.1320.9819-78.1328
Inactive00.30.5018-6.6712640 0 0 0 0 0 0 0 0 0 0 0 0 0-4.483807.84125.0947-0.36850.9766-4.3547-0.66533.21310-2.6766-3.7672-6.3927-2.7561-4.4838QC'd by NCIInactive0
Cytotoxic33.491553.023520Single point of activity-4.47514.95490.9093-57.314-4.2905-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.2755-6.13-5.7216-6.0909-1.1322-4.0113-6.953-0.8667-0.5352-3.8081-2.7523-6.4736-0.2391-14.0348-4.1839-50.2755QC'd by SigmaAldrichCytotoxic33.491543.216120Single point of activity-4.47514.95490.9489-44.7217
Inactive03.06540.64480.20834.321840 0 0 0 0 0 0 0 0 0 0 0 0 0-18.894333.038234.043-6.70165.11124.24770.05467.51211.52441.08954.9424.91169.6713-8.8416-18.8943QC'd by NCICytotoxic33.491538.402820Single point of activity-4.47514.95490.832-38.6215
Inactive04.95490.7541-3.03628.540 0 0 0 0 0 0 0 0 0 0 0 0 0-1.65425.818611.123-2.6648-5.527-2.1108-0.7834-0.2795-1.3292-6.2801-5.9904-3.6693-1.3675-3.1321-1.6542QC'd by NCIInactive04.95490.3332-0.5
Inactive04.95490.84961.39232240 0 0 0 0 0 0 0 0 0 0 0 0 04.046617.94353.1030.41822.1955-0.17152.82353.96390.0788-0.239-2.58983.38281.79160.39744.0466QC'd by NCIInactive04.50450.9224-0.7305
Inactive03.51170.39273-1.695140 0 0 0 0 0 0 0 0 0 0 0 0 0 02.3532-0.7162-0.0074-1.51420.6742-1.9219-3.891-3.1053-2.3524-2.8619-0.949-1.1980.6682-4.74592.1422.3532QC'd by NCIInactive0
Cytotoxic31.2143.456620Single point of activity-4.50574.95490.7461-46.3321-2.8755-30 0 0 0 0 0 0 0 0 0 0 0 0 0-45.4236-23.2298-4.49953.3316-2.32112.1332-2.31951.5412-1.1787-5.146-0.56271.3154-5.0727-6.7293-45.4236QC'd by NCICytotoxic26.603238.826420Partial curve; partial efficacy-4.57513.1320.8519-40.8264
Cytotoxic26.603234.702920Partial curve; partial efficacy-4.57512.40640.9771-38.2666-3.5637-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.0555-4.6672-2.5088-5.4716-4.3602-4.1809-2.6891-4.1367-1.8067-1.3031-4.0865-2.8527-4.2279-4.8434-16.0218-31.0555QC'd by LabotestInactive03.06540.7575-18.2037
Cytotoxic31.2126.94420Partial curve; partial efficacy; poor fit-4.50574.95490.8037-24.9442-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-24.1210.59991.3585-0.3563-0.60562.1079-1.54786.16642.4623-1.89281.97841.18620.52481.7585-24.12QC'd by NCICytotoxic33.491527.372520Partial curve; partial efficacy; poor fit-4.47514.95490.8005-26.3725
Inactive01.62660.7987-19.85024.540 0 0 0 0 0 0 0 0 0 0 0 0 0-14.87519.4894-1.33438.71942.60745.36513.28525.9036.96833.64690.0211-0.04561.4841-14.2523-14.8751QC'd by NCIInactive0
Inactive047.36137.5196-7.3951-0.70231.14315.96320.48820.14911.02055.83171.3822-0.343410.53266.96547.3613QC'd by NCIInactive0
Cytotoxic31.2131.422720Single point of activity-4.50574.95490.8431-33.9227-2.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2689-9.9006-5.5288-1.4219-0.0243-6.7803-3.4216-2.11071.4914-3.4573-1.8023-3.3297-0.1019-0.8542-33.2689QC'd by NCICytotoxic33.491551.227920Single point of activity-4.47514.95490.8738-54.2347
Inactive048.1128-3.52191.60923.5704-3.05675.54251.1281.79473.9211.45843.09545.7098-1.1492.90538.1128QC'd by NCIInactive0
Inactive04.95490.54013-7.823740 0 0 0 0 0 0 0 0 0 0 0 0 01.1178-1.9427-14.01981.42342.61488.01592.12438.1348-0.05886.06141.26242.49191.59630.22081.1178QC'd by NCIInactive0
Inactive043.42253.6223-3.44319.3218-0.1732-0.80331.8093-2.39193.81192.1766-1.5835-1.20313.85931.62713.4225QC'd by NCIInactive04.95490.38771
Inactive04.95490.42743.5-1.818940 0 0 0 0 0 0 0 0 0 0 0 0 0 04.6673-1.0353-6.09910.1105-0.7736-1.0905-3.54160.56970.18692.2758-5.4321-2.2238-3.56285.220.99214.6673QC'd by ChembridgeInactive0
Cytotoxic27.815930.261720Partial curve; partial efficacy; poor fit-4.55574.95490.7703-27.76172.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-26.4681-2.20990.61468.7045-3.0357-3.4205-0.0515-0.023510.83455.83643.293.32762.2442-2.1893-26.4681QC'd by NCIInactive04.95490.7812-21.5734
Inactive04-7.12970.2395-3.92457.56442.93285.83127.2431-2.9052-0.36468.84164.56552.17381.58961.9706-7.1297QC'd by NCIInactive04.50450.5518-8.9683
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:IucA Synthetase from hypervirulent Klebsiella pneumoniae hvKP1
External ID: IucA Pilot Assay Spectrum Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
1.054109.5793076877485A04
1.048108.5123881216295A05
1.085115.0917254460325A06
1.154127.3613004564045A07
1.12121.3154229150615A08
1.115120.4263232766295A09
1.126122.3823424811815A11
1.154127.3613004564045A12
1.138124.5161816134195A13
1.17130.2064192993895A14
1.155127.5391203840915A16
1.128122.7379823365545A17
1.156127.7169403117785A18
1.053109.4014877600625A19
1.052109.2236678323755A20
1.067111.8909667476735A21
1.032105.6672692786445A22
1.062111.0018671092415B03
1.091116.1586450121515B06
1.108119.1815837828235B08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=ATPase family AAA domain-containing protein 5; AltName: Full=Chromosome fragility-associated gene 1 protein
External ID: ELG271
Protocol: Please refer to other AIDs 651632 and 651634 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ATAD5 assay (AID 651632) and cell viability counter screen (AID 651634). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryATAD5 ActivityATAD5 Potency (uM)ATAD5 Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist19.3311819612.17977568inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0TCI
inactiveinactive0inactive0Alfa Aesar
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inconclusive antagonistinconclusive antagonist-22.16843258active antagonist30.63785869-80.36907549SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid hormone receptor beta isoform 2 [Rattus norvegicus]
External ID: TRN186
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37 C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo Luciferase Assay reagent (Promega) was added to each well using a Bioraptr FRD (Beckman Coulter), followed by 30 min incubation at room temperature. The luminescence intensity of plates was recorded by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.0950.3471-11.4032.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.50250.1158-3.1697-0.33515.6720.861714.90173.38536.9176-0.23470.4322-0.26143.98420.0305-0.2471-9.5025QC'd by NCIInactive0
Inhibitor8.4127111.383Complete curve; high efficacy-5.07514.50450.9828-108.24563.0545-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-112.7558-1.15723.06639.00343.54455.92481.74539.42291.34811.146-12.38566.95031.0946-61.7744-103.2834-112.7558QC'd by NCIInhibitor11.8832114.52442Partial curve; high efficacy-4.92512.95230.9725-113.8942
Inhibitor33.4915108.428710Single point of activity-4.47514.95490.9805-106.41752.0112-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.3487-0.0130.29265.8092.3543-1.529-1.86081.7268-1.32142.07110.45466.4268-1.17365.0616-1.2831-93.3487QC'd by NCIInhibitor33.491545.255310Single point of activity-4.47514.95490.8805-44.8499
Inhibitor6.6824112.359884Complete curve; high efficacy-5.17512.72020.9976-112.35980-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-107.86851.8367-0.98520.055-0.0873-0.0192-0.22741.70630.4571-0.0314-1.0907-6.2723-21.2839-82.4952-110.1566-107.8685QC'd by SigmaAldrichInhibitor11.8832118.081443Partial curve; high efficacy-4.92511.80790.9544-118.7095
Inhibitor6.6824105.669684Complete curve; high efficacy-5.17514.95490.9938-106.8079-1.1383-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-105.07267.23320.2468-0.2504-1.5237-2.6002-3.7474-7.12-3.24092.46950.0289-2.5534-12.3799-89.7924-106.5947-105.0726QC'd by NCIInhibitor9.4392121.220283Complete curve; high efficacy-5.02513.990.9879-117.3663
Inactive01.39870.58200.743840 0 0 0 0 0 0 0 0 0 0 0 0 0 16.5615-1.2435-1.42584.69634.22561.3627-6.880211.4156-5.29793.471-0.63623.942610.207711.431217.98796.5615QC'd by NCIInactive04.95490.50497
Inactive048.6584-0.25360.6070.1862-7.14463.14683.8879-0.6670.72263.43975.19140.62353.6739-0.02550.89198.6584QC'd by NCIInactive00.80.38469
Inactive0410.54210.43950.42364.47171.1049-1.458613.91965.5002-1.05963.065-7.07060.06181.202510.164811.16310.5421QC'd by NCIInactive03.990.606418
Inactive04-2.79550.91070.63340.0441-1.57746.62466.8752-6.6198-1.914714.01640.09133.5513.40912.4192-0.0362-2.7955QC'd by NCIInactive01.82650.72117
Inhibitor29.849398.496140Partial curve; high efficacy-4.52512.58840.9136-98.06750.4287-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-74.29356.770611.4199-0.0327-7.65161.0084-7.6141-0.0057-4.1882-0.0137-5.30869.05936.513-11.2634-24.6953-74.2935QC'd by LabotestInhibitor23.710181.201341Partial curve; high efficacy-4.62511.62660.9814-85.328
Inhibitor11.8832113.855282Complete curve; high efficacy-4.92513.51170.9826-115.6541-1.7989-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-108.9022-2.57351.71220.0161-0.9518-6.581711.0269-0.7611-7.71670.0417-2.5311-7.3404-6.9128-34.9326-107.0686-108.9022QC'd by NCIInhibitor13.3332117.674582Complete curve; high efficacy-4.87513.1320.9752-119.5106
Inhibitor11.8832100.560342Partial curve; high efficacy-4.92512.30310.9844-98.40762.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.4781-3.68021.45591.078-0.28983.594211.15550.03471.61545.5371-0.609-0.03380.0197-37.731-72.8614-96.4781QC'd by NCIInhibitor11.8832104.835482Complete curve; high efficacy-4.92512.84730.9729-101.2413
Inactive049.109716.353612.83932.63922.84184.686310.95966.499811.73249.79221.807413.675211.786911.24189.60329.1097QC'd by NCIInactive04.95490.571320.5
Inhibitor9.4392111.014483Complete curve; high efficacy-5.02513.06540.9851-108.05722.9572-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-104.01842.36323.22810.98985.081712.35020.2029-2.0107-1.81368.62391.97771.5258-9.3399-43.8626-105.9384-104.0184QC'd by NCIInhibitor11.8832117.796983Complete curve; high efficacy-4.92513.51170.9855-119.6341
Inactive01.10.49998.50.760140 0 0 0 0 0 0 0 0 0 0 0 0 0 06.7333-1.17177.005-0.40612.2711-1.86660.092310.02274.12186.31389.59344.80676.54059.438813.04816.7333QC'd by NCIInactive03.51170.516322
Inhibitor23.710130.537110Partial curve; partial efficacy; poor fit-4.62514.44950.7197-30.53710-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1975-0.68221.0324-2.45350.1458-0.1477-0.2161-13.6864-3.44241.79450.06561.3783.68649.5588-10.7074-29.1975QC'd by NCIInactive04.95490.9007-21.9629
Inactive0413.5114-0.54170.0115-0.029211.3153-0.00342.57815.33694.0109-1.29990.1952.6113-0.1351-0.43365.290313.5114QC'd by NCIInactive00.80.552326
Inactive040.5778-0.8927-0.3832-2.6058-1.17790.83535.6138-2.89484.8776-1.355-0.2164-10.3629-1.68473.3283-2.910.5778QC'd by ChembridgeInactive0
Inhibitor26.603248.396120Partial curve; partial efficacy-4.57514.95490.9177-49.2222-0.826-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.4351-2.3640.3688-9.6388-2.3442-2.041-0.00221.4733.1991-2.8675-0.6678-2.01651.02016.8251-11.741-46.4351QC'd by NCIInhibitor26.603240.019410Single point of activity-4.57514.95490.7816-36.0194
Inhibitor21.131779.094741Partial curve; high efficacy-4.67513.51170.7387-73.1775.9177-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.1538-0.9821-2.4893-8.8857-2.70951.21070.3298-0.1518-3.40975.743516.504521.713139.4410.1435-33.7222-68.1538QC'd by NCIInhibitor33.491568.810410Single point of activity-4.47514.95490.782-64.8654
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TRV455
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.95490.51575.6094-10.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-27.8709-9.58131.553-23.1602-8.9484-8.346419.02864.562714.53951.15650.42210.27193.49757.10181.1664-27.8709QC'd by NCIInactive0
Cytotoxic11.8832114.332782Complete curve; high efficacy-4.92513.92950.9541-100.920113.4126-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.18524.113126.147419.56668.33238.270922.114823.359311.62112.5923-0.271521.57888.2783-15.4501-95.7853-95.1852QC'd by NCICytotoxic13.3332101.165782Complete curve; high efficacy-4.87513.51170.924-104.4065
Cytotoxic33.491569.601420Single point of activity-4.47514.50450.5249-51.740917.8605-30 1 0 0 0 0 0 0 0 0 0 0 0 0 0-39.633934.934439.865511.20360.12813.12894.307410.103240.163543.97149.337135.80113.21470.805410.5036-39.6339QC'd by NCIInconclusive10.590945.114210Single point of activity-4.97510.80.518447.3375
Cytotoxic8.412795.006983Complete curve; high efficacy-5.07511.96730.9579-102.9662-7.9593-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-94.1612-1.6767-10.7501-18.3328-8.44320.3012-1.3116-10.0891-5.1512-10.2638-22.1904-3.3436-24.9807-62.5458-94.2914-94.1612QC'd by SigmaAldrichCytotoxic11.883290.158242Partial curve; high efficacy-4.92511.59360.9327-91.6733
Cytotoxic7.497881.846383Complete curve; high efficacy-5.12512.33320.9281-89.6388-7.7925-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-91.0963-18.97671.8287-17.872-12.3952-7.6161-16.3335-2.8335-2.6272-3.7796-9.8936-2.6598-12.2011-70.0356-74.6023-91.0963QC'd by NCICytotoxic7.497889.379383Complete curve; high efficacy-5.12512.40640.958-91.4223
Inactive049.32249.077510.90740.011913.6377.6888-14.85723.0077-6.11470.1121-5.92519.31916.946521.403721.67069.3224QC'd by NCIInactive0
Inactive048.728114.5817-0.06687.0683-0.16080.00131.578912.1056-2.13575.0113.2012-0.24876.3162-7.20095.40878.7281QC'd by NCIInactive04.95490.3678-32.6446
Inactive01.96730.466926.51032.587640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.33589.20266.9567-7.84944.72089.308420.04687.737-11.6312.3017-13.68133.162210.305816.449622.830726.3358QC'd by NCIInactive03.06540.3751-0.4202
Cytotoxic26.603233.620Partial curve; partial efficacy; poor fit-4.57513.990.6032-35.6-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.1667-19.4025-0.1543-0.2262-0.0757-11.09324.6638-6.5718-3.54455.09010.036-2.1840.10135.1383-12.1502-32.1667QC'd by NCIInactive0
Cytotoxic29.849380.614440Partial curve; high efficacy-4.52513.24750.7249-82.8026-2.1882-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.04879.32489.4674-17.343-9.0088-18.8502-4.8122-4.1352-5.0412-6.7317-5.864410.034619.8329-8.8964-20.6155-67.0487QC'd by LabotestCytotoxic29.849363.527240Partial curve; partial efficacy-4.52512.72020.9071-66.8238
Cytotoxic13.3332104.692182Complete curve; high efficacy-4.87513.51170.9601-100.33534.3568-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.17277.15452.81146.9308-0.1572-4.105825.3068-0.15731.08666.05980.85484.7774-0.6992-14.6485-90.6892-99.1727QC'd by NCICytotoxic16.7855114.729642Partial curve; high efficacy-4.77512.25260.9303-115.7849
Cytotoxic26.603293.069640Partial curve; high efficacy-4.57512.58840.7505-86.42426.6454-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.9291-25.457521.195211.0147-3.417213.682328.16354.114810.73649.90963.39471.32276.46260.2705-23.9356-68.9291QC'd by NCICytotoxic26.603283.904440Partial curve; high efficacy-4.57513.62720.9084-83.7035
Inactive0418.582530.92839.765411.01316.57590.04867.97495.3184.25971.95691.324516.866511.719816.94696.665118.5825QC'd by NCIInactive0
Cytotoxic10.590994.271582Complete curve; high efficacy-4.97512.72020.9664-98.4917-4.2203-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.2687-12.6266-9.71552.76191.16913.9341-2.1458-8.3456-7.78480.2987-4.4158-14.4266-11.7198-37.3785-91.2452-93.2687QC'd by NCICytotoxic10.590995.537682Complete curve; high efficacy-4.97512.40640.9837-98.3736
Inactive0421.512319.121525.006-1.94118.35391.0147-1.112212.94014.543614.711516.23313.403818.402626.76119.601221.5123QC'd by NCIInactive0
Inactive02.53340.618314.3567-5.901840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9449-6.97990.27957.2032-12.5846-2.9847-20.5724-7.1225-1.8195.056311.806413.728118.906723.71122.022-7.9449QC'd by NCICytotoxic33.491533.929720Single point of activity-4.47514.95490.5032-33.6955
Inactive0422.09676.01187.77648.964524.48872.336215.856811.60168.99512.18910.87535.056316.9556-9.06529.599522.0967QC'd by NCIInactive02.24810.359418.3831
Inactive04.95490.412622-0.482840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.1783-1.3463-1.5399-1.530212.584-0.6727.8822-4.87790.9615-0.7224-1.1373-9.9856-1.498-1.70110.588816.1783QC'd by ChembridgeInactive0
Cytotoxic29.849359.759320Single point of activity-4.52514.95490.7823-51.55738.202-30 0 0 0 0 1 0 0 0 0 0 0 0 0 0-45.047813.2325.4558-6.067513.70124.8368-25.68159.851213.6578.28768.3941-6.470517.960418.9919-1.1526-45.0478QC'd by NCICytotoxic33.491560.182320Single point of activity-4.47514.95490.9381-56.7139
Cytotoxic33.491577.960640Partial curve; high efficacy-4.47513.51170.6902-85.5053-7.5447-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.8614-23.92-6.4036-24.81696.0929-7.6795-2.09631.7283-20.9170.4558-10.7547-17.85467.586-12.7766-19.5831-67.8614QC'd by NCICytotoxic33.491567.176140Partial curve; high efficacy-4.47514.95490.7237-73.9128